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Abstract 
The cholinergic-dopamienrgic reward link and addictive behaviours 
-special emphasis on ethanol and ghrelin 
 
Elisabet Jerlhag 
Institute of Neuroscience and Physiology, Section for Pharmacology, 
The Sahlgrenska Academy at Göteborg University, BOX 431, SE-405 
30 Göteborg, Sweden. 
 
An important part of the reward systems is the cholinergic-
dopaminergic reward link. This reward link has been proposed to be 
involved in reward and motivated behaviours. It encompasses a 
cholinergic input from the laterodorsal tegmental area (LDTg) to the 
mesolimbic dopamine (DA) system that originates in the ventral 
tegmental area (VTA) and projects to the nucleus accumbens.  
Previous results demonstrate that nicotinic acetylcholine receptors 
(nAChRs), especially those located in the VTA, are involved in 
mediating the stimulatory, rewarding and DA enhancing properties of 
ethanol. One aim of the present thesis was therefore to investigate the 
functional role of different nAChR subtypes for the behavioural and 
neurochemical effects of ethanol. In Paper I a slightly modified 
method was used to synthesize ?-conotoxins with various subunit 
selectivity; ?-conotoxin MII (?CtxMII) and a ?-conotoxin PIA-
analogue. Furthermore, it was demonstrated that ?CtxMII-sensitive 
(i.e. the ?3?2*, ?3* and/or ?6* subtypes), rather than ?PIA-analogue-
sensitive (the ?6* subtype), nAChRs in the VTA are involved in 
mediating the stimulatory and accumbal DA enhancing properties of 
ethanol. Given that ethanol concomitantly increases ventral tegmental 
ACh and accumbal DA levels and that some of the effects of ethanol 
are mediated via the ?3?2* and/or ?3*, rather than ?6* subtypes in the 
VTA, we hypothesize that ethanol activates the cholinergic-
dopaminergic reward link. 
There appears to be a neurochemical overlap between the reward 
systems and the systems regulating energy balance. Ghrelin is an 
orexigenic peptide, which e.g. via the hypothalamus increases food 
intake. Given that ghrelin is involved in energy balance regulation, the 
role for ghrelin in brain reward was investigated in Papers II, III, IV. It 
was demonstrated that intracerebroventricluar administration of 
ghrelin increases locomotor activity and accumbal DA overflow in 
mice, suggesting that ghrelin activates the mesolimbic DA system. In 
subsequent experiments it was found that administration of ghrelin 
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into either the LDTg or the VTA (reward nodes expressing growth 
hormone secretagougue receptors (GHSR-1A)) increases the 
locomotor activity as well as accumbal DA overflow. Thus indicating 
that ghrelin, via GHSR-1A in the LDTg and/or VTA, activates the 
cholinergic-dopamine reward link. Further, the stimulatory and DA 
enhancing properties of ghrelin (intracerebroventricluar) were 
antagonized by systemic administration of the unselective nicotinic 
antagonist, mecamylamine, implying that cholinergic mechanisms are 
involved in mediating the stimulatory and DA enhancing effects of 
ghrelin. Additionally, it was showen that the stimulatory and DA 
enhancing effects of ghrelin administration (into either the VTA or 
LDTg) were mediated via ?CtxMII-sensitive nAChRs, i.e. the ?3?2* 
and/or ?3* subtypes, in the VTA, implying neurochemical analogies 
between ethanol and ghrelin. These findings provide the first 
indication that ghrelin has a role in brain reward and that ghrelin is a 
part of the neurochemical overlap between systems regulating energy 
balance and reward. We hypothesize that ghrelin stimulates the 
cholinergic-dopaminergic reward link and thereby increases the 
incentive values of signals associated with motivated behaviours such 
as food searching/foraging. Thus ghrelin drives animals (and man) to 
work and to seek for food. High plasma levels of ghrelin have been 
associated with some aspects of binge eating/compulsive overeating as 
well as alcoholism. Additionally, a deranged reward system has been 
implicated in overeating and alcoholism. We therefore hypothesizes 
that hyperghrelinemia, via activation of the cholinergic-dopaminergic 
reward link, may be a part of the pathophysiology of binge eating and 
alcoholism. The findings in the present thesis demonstrate that the 
?3?2* and/or ?3* subtypes are involved in mediating the stimulatory 
and DA enhancing effects of ethanol and ghrelin. It is therefore 
suggested that these subunits might be novel pharmacological targets 
for treatment of compulsive overeating as well as alcoholism. 
 
Key words: ethanol, ghrelin, reward, food-seeking, ventral tegmental 
area, laterodorsal tegmental area, nucleus accumbens, dopamine, 
nicotinic acetylcholine receptors, in vivo microdialysis, locomotor 
activity, mice, addictive behaviours. 
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Introduction 
Addiction 
Addiction is a chronic, relapsing brain disorder (Hunt et al, 1971; 
Leshner, 1997; McLellan et al, 2000), characterized by a compulsive 
drug-seeking behaviour and a loss of control (Koob and Le Moal, 
2001). Substance use is defined as a controlled drug intake for non-
medical purposes, whereas substance abuse is a harmful drug intake 
that is continued despite negative effects. Substance use or abuse 
causes substance dependence in some, but not all, individuals. The 
definition for substance dependence is described in the Diagnostic and 
statistical manual of mental disorders 4th edition (table 1).  
 
 
Table 1. Diagnostic criteria for substance dependence as described in the 
Diagnostic and statistical manual for mental disorders.  
Substance dependence is defined by the occurrence of three (or more) of the following 
criteria, over a continuous 12-month period. 
 
With new perspectives and knowledge, the general idea of addiction as 
substance dependence has changed. Clinical studies of patients with 
aberrant eating behaviour have shown behavioural parallels between 
compulsive overeating and chemical addictions (e.g. nicotine, alcohol 
and psychomotor stimulants) (Davis and Claridge, 1998; Davis, 2001; 
Davis and Woodside, 2002). Additionally, it has been shown that food, 
when consumed in excess and over time, can cause the same brain 
neuroadaptations as drug abuse (e.g. Grigson, 2002). It has therefore 
been suggested that brain functions can be similarly derailed by natural 
rewards and drugs of abuse. “Behavioural” addictions, such as 
compulsive overeating, gambling and compulsive shopping, have 
1. Tolerance
2. Withdrawal
3. The substance is taken in larger amounts or over a longer period than
intended (i.e. loss of control)
4. There is a persistent desire or unsuccessful effort to cut down or control
substance use (i.e. craving)
5. A great deal of time is spend in activities necessary to obtain and use the
drug as well as recover from its effects
6. Important social, occupational or recreational activities are reduced or
given up due to the substance use
7. The substance use is continued despite knowledge of having a persistent
or recurrent physical or psychological problem that is likely to have been
caused or exacerbated by the substance
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therefore been included in the definition of addiction and are together 
with drug dependence called addictive behaviours. Interestingly, 
human imaging studies have revealed that there is an underlying 
disruption in the reward systems in the brain (Holden et al, 2001; 
Knutson et al, 2001; Potenza et al, 2003; Volkow et al, 2003a; Volkow 
and Li, 2004; Wang et al, 2004a; Reuter et al, 2005), as well as in brain 
regions important for inhibitory control (Volkow et al, 2003b) in 
addictive behaviours. 
 
A number of theories approach the causes for addiction, including the 
drug-centred and/or the individual-centred hypothesis. The drug-
centred theory suggests that a chronic use of a drug or chronic 
disrupted behavioural patterns causes molecular changes within the 
brain, e.g. in the dopamine (DA) reward systems (vide infra), which shifts 
the individual’s behaviour from a normal approach to a state of 
addiction (Berke and Hyman, 2000; Hyman and Malenka, 2001; 
Nestler, 2001; Deroche-Gamonet et al, 2004). In contrast, the 
individual-centred hypothesis implies that individuals likely to become 
dependent are born with an increased vulnerability in the reward 
systems (Wolf and Maisto, 2000), such as a dopaminergic hypo- 
and/or hyper-function. It has been hypothesized that a dopaminergic 
hypo-function causes a reward deficit syndrome (Balldin et al, 1985; 
Volkow et al, 1990; Balldin et al, 1992; Volkow et al, 1993; Volkow et 
al, 1996; Wang et al, 1997; Volkow et al, 2001; Wang et al, 2004a; 
Bowirrat and Oscar-Berman, 2005) and hence individuals with a 
reward deficit syndrome excessively use rewards in a compensatory 
manner to increase the DA levels to an ambient level. On the other 
hand, augmentation of DA signalling increases the desire to eat in 
response to a palatable food cue (Volkow et al, 2002), implicating that 
increased DA function may cause an enhanced hedonic capacity 
(Cohen et al, 2005). This hyper-function in DA signalling makes 
individuals more sensitive to rewards (Davis et al, 2004). It is thus 
plausible these individuals will gain more gratification out of a reward 
than subjects with low sensitivity to reward, making them more prone 
to develop an addiction (Davis et al, 2004). Taken together, it may be 
concluded that individuals with a high sensitivity to reward are driven 
to excessively use rewards and that this over stimulation over time may 
cause a down regulation of the mesolimbic DA system. Additionally, it 
should be emphasized that age, genetics and hormonal status are 
essential factors influencing the individual’s risk to develop an 
addiction (Engel et al, 1992). Conclusively, it is most probable that 
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both the drug-centred and individual-centred theories make valid 
points to the conceiving of addiction (Deroche-Gamonet et al, 2004). 
Needless to say, the plethora of hypothesis regarding the causes of 
addiction point at the complexity of this disease.  
 
Alcoholism 
Alcohol dependence is a chronic disorder (Garbutt et al, 1999) and is 
today recognized as a disease. Attempts have been made to classify this 
heterogeneous disease into different subtypes (e.g. Cloninger et al, 
1988; Lesch et al, 1988). It should be taken to consideration that 
different neurochemical, genetical and psychological factors are 
involved in the development of the subtypes of alcohol use disorder, 
thus implying that differential treatment strategies may be applied. 
Alcoholism causes considerable suffering to the individual as well as to 
their families and society (Garbutt et al, 1999). Patient related 
problems include decreased health status, malnutrition, liver damage 
and cardiovascular problems (Bien and Burge, 1990). The direct and 
indirect health and social costs related to alcoholism in Sweden is 
annually estimated to be tens of billions of Swedish crowns, due to 
factors such as loss of production, social welfare and medical costs. 
 
Alcoholism and smoking 
Alcohol and nicotine are the most commonly abused drugs all and are 
often co-abused. Both smoking and alcoholism are major public health 
problems (Walton, 1972) and the combination of the two increases the 
risk of bad health substantially (Bien and Burge, 1990). Several clinical 
and epidemiological studies have demonstrated an association between 
high alcohol consumption and the use of tobacco and vice versa (e.g. 
Walton, 1972; Craig and Van Natta, 1977; Istavan and Matarazzo, 
1984; Mello et al, 1987; Bien and Burge 1990; DiFranza and Guerra, 
1990; Zacny, 1990; Miller and Gold, 1998). For instance, 
approximately 90 % of all alcoholics smoke, which is a much higher 
percentage than for the average population (Walton, 1972; Ayers et al, 
1976; Bien and Burge, 1990, Batel et al, 1995; Miller and Gold, 1998). 
A clinical trial by Dawson (2000) showed that the prevalence for 
lifetime smoking is the highest among former drinkers compared to 
abstainers from alcohol and past-year drinkers. Additionally, smokers 
consume twice as much alcohol as non-smokers (Carmody et al, 1985) 
and alcoholism is estimated to be 10 to 14 times more common among 
smokers than non-smokers (DiFranza and Guerrera, 1990; Daeppen et 
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al, 2000). In addition, nicotine dependent individuals have a greater 
severity of alcohol dependence (Daeppen et al, 2000) and alcoholics 
fail to quit smoking to a greater extent than non-alcoholics (DiFranza 
and Guerrera, 1990). Interestingly, in some studies ethanol has been 
found to potentiate the rewarding effects of nicotine in smokers (Rose 
et al, 2004) and nicotine increases the motivation to consume ethanol 
in male, non-dependent smokers (Barrett et al, 2006). These effects 
may be some of the reasons for the co-abuse of ethanol and nicotine, 
however other contributors may be psychosocial and environmental 
factors. Interestingly, there also appears to be a strong correlation 
between an early onset of tobacco abuse and addiction to alcohol later 
in life (DiFranza and Guerrera, 1990; Grant, 1998). Moreover, nicotine 
use during pregnancy may cause alcohol dependence in the next 
generation (Brennan et al, 2002; for review see Hellström-Lindahl and 
Nordberg, 2002), indicating that early exposure to nicotinic may 
contribute to an increased risk of alcoholism.  
Pre-clinically, it has been reported that the ethanol intake and 
preference increases significantly following sub-chronic nicotine 
treatment in rat (Potthoff et al, 1983, Blomqvist et al, 1996; Ericson et 
al, 2000; Lê et al, 2000; Clark et al, 2001; Olausson et al, 2001). 
Furthermore, nicotine reinstates the alcohol-seeking behaviour in rats 
during drug-free periods (Lê et al, 2003). Additionally, simultaneous 
administration of lower doses of ethanol and nicotine potentiates DA 
release in the N.Acc. (Tizabi et al, 2002), suggesting that nicotine 
enhances the rewarding properties of ethanol. 
As discussed above the neurochemical basis underlying the 
development of alcoholism is still unknown. However, these clinical 
and pre-clinical findings, suggest that ethanol and nicotine may share 
important neurochemical mechanisms of action in the brain reward 
systems such as those involving nicotinic acetylcholine receptors 
(nAChR) (for review see Larsson and Engel, 2004). 
 
Pharmacological treatment 
A century ago Merck Manual recommended cocaine to remove craving 
for alcohol and spirit of ammonia as a substitute for alcohol. The 
treatment of patients with alcohol dependence has changed 
considerably since then. Individual and group counselling have been, 
and still are, basic elements in the rehabilitation of alcohol dependent 
patients (Kranzler, 2000). The combination of psychological and 
pharmacological treatment is another alternative (Garbutt et al, 1999). 
The drastic increase in knowledge of specific areas and 
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neurotransmitter systems in the brain involved in drug reinforcement 
has resulted in the development of new pharmaceutical agents. In 
animal studies such agents have been efficient in decreasing alcohol 
intake, whereas a few have been efficient in clinical studies (Kranzler, 
2000). The first drug approved for alcohol use disorder was the 
deterrent drug disulfiram (Antabus?), which makes the ingestion of 
alcohol unpleasant (Kranzler, 2000). Two other pharmaceuticals have 
been approved for alcohol use disorder (acamprosate (Campral?) and 
naltrexone (Revia?)), although they are not fully efficient and thus the 
need for novel treatment strategies remains. It is therefore vitally 
important to further study the neurobiological mechanisms involved in 
alcohol use disorder and this is one of the aims of the present thesis.  
 
Compulsive overeating/binge eating 
Individuals with an imbalance between energy intake and expenditure, 
where the former is in favour, are often over weight and obese as a 
result (for review see Hellström et al, 2004). Approximately 30% of 
obese subjects who participate in weight loss programs have binge 
eating disorder (BED) (for review see Yanovski, 1993; De Zwaan et al, 
1994). Subjects with BED overeat with a sense of loss of control and 
do not engage in inappropriate compensatory behaviour afterwards 
(for review see Yanovski, 1993; Yanovski, 1995). One of the most 
common genetic causes of obesity is the Prader-Willi syndrome, which 
is characterized by symptoms such as severe hyperphagia, mental 
retardation and hypogonadism (Holland et al, 1993; Holm et al, 1993). 
Aberrant patterns of eating behaviour, weight regulation as well as 
disturbed attitudes towards weight, shape and perception of body 
shape characterize both anorexia nervosa and bulimia nervosa (for 
review see Kaye et al, 2000). Anorexia nervosa, a fear of fatness and an 
obsession with fatness, can be divided into two subtypes: restrictive 
and binge eating. The restriction subgroup is characterized by food 
avoidance and malnutrition, whereas the binge eating subtype is 
distinguished by periods of bingeing followed by self-induced vomiting 
or laxative abuse (Strober, 1980). Patients with bulimia nervosa have 
irregular eating patterns and impaired satiety. The core features include 
repeated periods of binge eating followed by compensatory behaviours 
to counteract weight gain e.g. vomiting, laxative abuse or extreme 
exercise, keeping the body weight in a normal range. The multi-
impulsive type and self-effecting type are two distinct subtypes of 
patients with bulimia nervosa. Interestingly, histories of substance 
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abuse or other addictive behaviours, e.g. shop lifting, and other 
impulse-control problems such as self-injuries are more common 
among the multi-impulsive type. Furthermore, they are also more likely 
to binge eat to regulate anger and tension. The self-effecting type are 
more likely to binge eat to reduce the feelings of guilt associated with 
weight gain (for review see Kaye et al, 2000). Interestingly, bulimic 
individuals have higher sensitivity to reward than the subjects with 
restrictive type of anorexia nervosa, indicating that bulimic patients are 
more sensitive to the rewarding effects of food and drugs (Davis and 
Woodside, 2002).  
 
Compulsive overeating/binge eating is characterized by the persistent 
intake of large amounts of food during discrete periods of time and 
can be observed in anorexia nervosa, bulimia nervosa, Prader-Willi and 
obesity. Interestingly, the behaviours of binge eating individuals are 
very similar to that of a drug addict, including obsessive-
compulsiveness, impulsivity, sensation seeking and loss of control 
(Davis and Claridge, 1998; Davis, 2001; Davis and Woodside, 2002; for 
review see Cassin and von Ranson, 2005). Thus compulsive overeating 
is defined as an addictive behaviour (e.g. Davis et al, 2004; James et al, 
2004; Wang et al, 2004a; Corwin, 2006), and is thought to be caused by 
a dysfunction in the reward systems (Volkow et al, 2003a; Wang et al, 
2004a). Furthermore, functional magnetic resonance imaging (fMRI) 
scans have shown that the activation of the nucleus accumbens 
(N.Acc.) due to ingestion of oral glucose is delayed in Prader-Willi 
patients (Shapira et al, 2005); indicating that a dysfunction of the 
reward system may be involved in the pathophysiology of Prader-Willi 
syndrome.  
 
Aberrant eating patterns and drugs of abuse 
A co-morbidity of substance abuse and deviant eating behaviours is 
well documented in the literature (for reviews see Holderness et al, 
1994, Wolfe and Maisto, 2000; Bulik et al, 2004b). Nicotine use is 
more prevalent in individuals with eating disorders (Welsh and 
Fairburn, 1998; Wiseman et al, 1998). Several studies suggest that 
differences in smoking patterns may exist across the different subtypes 
of eating disorders (Bulik et al, 1991; Haug et al, 2001; Wiederman and 
Pryor, 1996), e.g. patients with bulimia nervosa have higher smoking 
prevalence than those with anorexia nervosa (Bulik et al, 1991; Haug et 
al, 2001). Additionally, women with eating disorder subtypes, that 
include binge eating, have been shown to score higher for nicotine 
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dependence (Anzengruber et al, 2006) and are more likely to smoke 
(Wiseman et al, 1998; Crisp et al, 1999). However, this difference was 
not observed in a recent community study (von Ranson et al, 2002). 
Patients with anorexia nervosa-restricting type showed no difference in 
smoking prevalence to controls (Anzengruber et al, 2006). 
Additionally, this subtype displays lower rates of other substance 
abuses, impulsivity and novelty seeking behaviours (for review see 
Bulik et al, 2004a; Bulik et al, 2004b; Klump et al, 2004). Dieting 
increases the risk of smoking in girls and the risk of smoking is 
positively correlated with the dieting frequency (Austin and 
Gortmaker, 2001). Additionally, alcohol consumption and bulimic 
behaviours have been suggested to be additive risk factors in smoking 
adolescents (Field et al, 2002). Furthermore, the abuse of alcohol is 
higher in patients with eating disorders than in the general population 
(Bulik et al, 2004a; for review see Bulik et al, 2004b). More specifically, 
in a review of 25 studies the prevalence of alcohol dependence in 
bulimic patients was estimated to 22.9% (Holderness et al, 1994). The 
prevalence of alcoholism varies with different subtypes of eating 
disorders, where alcohol abuse disorder is uncommon in the anorexia 
nervosa restrictive subtype but frequent in the binge eating subtype 
and in individuals with bulimia nervosa (Henzel, 1984; Bulik et al, 
1992; for review see Bulik et al, 2004b). Interestingly, a co-morbidity of 
bulimia and alcohol dependence has been found to be associated with 
other types of substance abuse, increased novelty seeking scores and 
impulsivity (Bulik et al, 1997). Furthermore, the lifetime rates of 
alcohol/drug dependence in first degree relatives to patients with 
bulimia nervosa is significantly higher than in first degree relatives to 
control individuals (Kaye et al, 1996). On the other hand, obese 
women have been found to display lower rates of alcohol (Kleiner et 
al, 2004) and marijuana use (Warren et al, 2005). Common 
neurobiological mechanisms may therefore be implied to underlie 
addictive behaviours such as compulsive overeating, alcoholism and 
nicotine dependence. 
 
The reward systems 
Since ancient times mankind has been using drugs to achieve euphoria 
and a state of well-being. During the last decades the neuronal systems 
within the brain mediating these feelings have progressively been 
identified. As early as in the middle of the 1950s Olds and Milner 
serendipitously discovered that rats would work to self-administer 
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electrical currents into some, but not into other brain areas (Olds and 
Milner, 1954). Interestingly, the rats pressed the lever repeatedly and 
their attention to natural rewards such as eating, drinking and breeding, 
vanished; they had become electricity-dependent (Phillips and Fiberger, 
1989). The rats had been implanted with electrodes in specific areas of 
the limbic system, a system involved in emotional experiences in both 
rodents and humans. These brain areas were later anatomically mapped 
in more detail and are today known to mediate reward, pleasure and 
euphoria and are therefore called the “reward systems”. The reward 
systems have been identified in flatworms as well as in other primitive 
animals, and are hence suggested to be highly conserved and stable 
throughout the evolution. An important role of these systems is to 
stimulate and enhance the motivation of behaviours that increase the 
probability of survival, such as foraging and drinking, as well as the 
continued existence of the species, e.g. breeding (Hansen et al, 1991; 
Schultz et al, 1997). Videlicet, these natural rewards are known to 
activate the reward systems in animals as well as in humans, inducing 
euphoria and a state of well-being. In humans, the modulation of the 
reward systems is more complex and varies substantially between 
individuals. It has been demonstrated in humans that a monetary 
reward (Pappata et al, 2002), music (Menon and Levitin, 2005), a 
picture of a pretty face (Kampe et al, 2001) and video games (Koepp et 
al, 1998) can activate the reward systems. However, humans as well as 
animals can learn to activate the reward systems artificially with 
addictive drugs, such as ethanol and nicotine, as well as by engaging in 
compulsive behaviours, e.g. compulsive shopping and compulsive 
overeating (for review see Miller, 1980; Holden, 2001). Direct electrical 
stimulation and habit-forming drugs are more powerful rewards than 
natural rewards and are hypothesized to hijack the reward systems 
(Wise and Rompre, 1989). A long-term consequence of such artificial 
activation may be a loss of interest for natural rewards and may thus 
cause drug/behavioural dependence.  
 
The mesocorticolimbic dopamine system 
Several brain regions involved in the reward systems have been 
identified and include the prefrontal cortex, hippocampus and N.Acc. 
(i.e. the ventral striatum). Through investigations of physiological 
responses to un-sensed incentives, such as intra-cranial stimulation and 
intra cranial drug injections, the mesocorticolimbic DA system has 
been identified as a common denominator of the reward systems (Wise 
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and Rompre, 1989). The mesocorticolimbic DA system consists of 
dopaminergic neurons originating in the ventral tegmental area (VTA) 
projecting via the medial forebrain bundle to several limbic structures, 
such as N.Acc. and the amygdala, and to cortical structures, e.g. the 
prefrontal cortex (see e.g. Dahlström and Fuxe, 1964; Ungerstedt, 1971; 
Engel et al, 1988; Koob, 1992a; Nestler et al, 2001). The dopaminergic 
projections to these areas are likely to differ with regard to 
neurobiology, electrophysiology and function and could therefore be 
divided into several different systems, such as the mesolimbic and the 
mesocortical DA system. More specifically, the mesolimbic DA 
system, i.e. the dopaminergic neurons projecting from the VTA to the 
N.Acc., have been suggested to create the most central part of the 
reward systems (see e.g. Koob, 1992a, Koob, 1992b) (Fig. 1), and are 
implicated in the shaping of goal-oriented behaviours driven by 
conscious or unconscious motivation (Schultz, 1998). The N.Acc. can 
be divided into two distinct anatomically and functionally different 
regions (Graybiel and Ragsdale, 1978), the central core and the 
surrounding shell (Voorn et al, 1989; Heimer et al, 1991; Zahm and 
Brog, 1992; Zahm, 1999).  
 
Fig. 1. The mesolimbic dopamine system. 
The dopaminergic cell bodies originate in the ventral tegmental area (VTA) and project 
to the nucleus accumbens (N.Acc.). Upon stimulation dopamine (DA) is released in 
the N.Acc.. 
 
The reinforcing effects of addictive drugs and palatable foods are 
dependent on activation of the mesocorticolimbic DA system (e.g. 
Engel et al, 1999; Risinger et al, 2000; Di Chiara et al, 2004), and it has 
been suggested that this system cannot differentiate among rewards 
provoked by natural reinforcers e.g. food, addictive drugs such as 
ethanol, or behaviours like gambling (Kelley et al, 2005).  
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Firing of the dopaminergic neurons in the VTA 
The DA neurons in the VTA typically display two basic modes of 
firing; a single spike-firing mode and a burst-firing mode (Grace and 
Bunney, 1984a; Grace and Bunney, 1984b; Grenhoff et al, 1986). 
Under normal conditions the DA neurons in the VTA are quiescent or 
fire with single spikes. When triggered by appropriate input the DA 
neurons can switch back and forth between the two modes. A change 
from single spikes to burst firing enhances and prolongs the signal 
strength, which in turn increases the DA levels in N.Acc. (Gonon, 
1988; Wightman and Zimmerman, 1990). This shift appears to 
originate from the excitatory amino acid inputs to the VTA (Overton 
and Clark, 1997) and may also cause a release of co-localized peptides 
(Bean and Roth, 1991). The functional relevance of burst firing in the 
reward circuits is not fully understood, however it is plausible that the 
switch from spikes to burst-firing is used to enhance the signals from 
salient events and dampen the signals from non-salient rewards. More 
specifically, it has been demonstrated that the DA neurons show 
phasic bursting activity in response to unexpected presentation of a 
novel food reward (Schultz, 2001) as well as of a conditioned stimulus 
that has been associated with food reward (Schultz et al, 1993). 
Furthermore, during the course of training, as the reward becomes 
expected, the DA neurons loose the phasic bursting. Interestingly, it 
has been shown that moderate food restriction causes a prolonged 
increase in the basal impulse activity and firing of the DA neurons, 
making the cells more attentive during particular motivational states. 
Given that spontaneous burst firing does not occur in brain slice 
preparation of DA neurons, it has been implied that the firing of these 
neurons is driven by afferent inputs (for review see Sanghera et al, 
1984).  
 
Reward and dopamine 
Accumbal DA release is widely believed to be involved in mediation of 
the rewarding, hedonic feelings of incentives, natural as well as artificial 
(e.g. Taylor and Robbins, 1984; Taylor and Robins, 1986; Wise and 
Bozarth, 1987; Engel et al, 1988; Cador et al, 1991; Robinson and 
Berridge, 1993), thus indicating that accumbal DA overflow is a 
common response to various reinforcers. Moreover, a role for DA in 
incentive salience (“wanting”), a motivated behaviour for reward, e.g. 
food searching, has been implied (for review see Berridge and 
Robinson 1998; Cannon and Palmiter 2003; Berridge 2004; 
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Kringelbach 2004). However, the theory of reward and DA has been 
challenged. Selective DA enhancement in the N.Acc. has been 
observed in associative learning in absence of biological reward, 
suggesting that the mesolimbic DA system is involved in associative 
learning in general, and not specifically in learning related to rewards 
(Spanagel and Weiss, 1999).  
 
Drugs of abuse, dopamine and reward 
The first evidence demonstrating a causal relationship between 
ethanol-induced stimulation of behaviour and catecholaminergic 
activity was that the catecholamine-synthesis inhibitor, ?-
methyltyrosine antagonized ethanol-induced stimulation as well as 
euphoria in humans (Ahlenius et al, 1973) and locomotor stimulation 
in rats (Engel et al, 1974). Microdialysis studies in freely moving rats 
showed that most drugs of abuse, including amphetamine, opiates and 
cocaine, increase the extracellular DA levels predominantly in the 
N.Acc. (Di Chiara and Imperato, 1988). Furthermore, it has been 
found that both ethanol (e.g. Imperato and Di Chiara, 1986; Engel et al, 
1988; Di Chiara and Imperato, 1988; Blomqvist et al, 1993; Olive et al, 
2000; Larsson et al, 2002; Larsson et al, 2004) and nicotine (e.g. Di 
Chiara and Imperato, 1988; Benwell and Balfour, 1992; Nisell et al, 
1994; Larsson et al, 2002; Ericson et al, 2003) increase the accumbal 
DA overflow in vivo in rodents. More specifically, increased DA levels 
are observed in the N.Acc. shell but not in the core (Cadoni et al, 
2000; Iyaniwura et al, 2001; Bassareo et al, 2003). Furthermore, it has 
been observed that voluntary oral ethanol-intake increases the 
accumbal DA levels in rats (Ericson et al, 1998; Doyon et al, 2003; 
Larsson et al, 2005), in a dose-dependent manner (Weiss et al, 1993). 
Additionally, intravenous administration of low doses of ethanol 
produces a dose-dependent increase in the firing rate of DA neurons 
in the VTA, which project to the ventral striatum (i.e. N.Acc.). On the 
other hand, the DA neurons, which project to the dorsal striatum, 
were activated to a lesser extent (Gessa et al, 1985). It has been 
proposed that this accumbal DA overflow represents the pleasure and 
euphoria experienced by alcohol consumption (e.g. Engel, 1977; Engel 
and Carlsson, 1977, Wise and Rompre, 1989). Interestingly, DA 
antagonists suppress the ethanol-induced locomotor stimulation 
(Liljequist et al, 1981). Moreover, several studies have reported 
alterations in ethanol intake, preference and oral self-administration 
following systemic and intra-accumbal administration of DA agonists 
or antagonists (Pfeffer and Samson, 1985a; Pfeffer and Samson, 1985b; 
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Pfeffer and Samson 1988; McBride et al, 1988; McBride et al, 1990; 
Weiss et al, 1990; Samson et al, 1991; Rassnick et al, 1993a; Rassnick et 
al, 1993b; Rassnick et al, 1993c; Samson et al, 1993; Hodge et al, 1997; 
Nowak et al, 2000). A role for accumbal DA in alcohol self-
administration may therefore be suggested. However, this theory has 
been challenged by several reports that describe the complex 
interaction between accumbal DA in ethanol consumption and seeking 
(Czachowski et al, 2001; Samson and Chappell, 2004). Additionally, the 
rewarding effects of addictive drugs are attenuated by a decreased 
dopaminergic neurotransmission (Engel, 1977; Wise, 1996; Maldonado 
et al, 1997; Risinger et al, 2000). A positron emission tomography 
(PET) study in humans demonstrate that oral ethanol consumption, in 
intoxicating doses, promotes DA release in the ventral striatum 
(Boileau et al, 2003). Similarly, psychostimulants (Carson et al, 1997; 
Schlaepfer et al, 1997; Drevets et al, 2001; Volkow et al, 2001; Leyton 
et al, 2002; Martinez et al, 2003) as well as rewarding behavioural tasks 
(Koepp et al, 1998) increase the DA activity in ventral striatum in 
humans measured by PET. Interestingly, the amount of released DA in 
the ventral striatum correlates with self-reported behavioural measures 
of euphoria or drug wanting (Volkow et al, 1997; Drevets et al, 2001; 
Leyton et al, 2002; Martinez et al, 2003). Furthermore, drugs that are 
not rewarding and not abused by humans do not modify synaptic 
accumbal DA levels (Di Chiara and Imperato, 1988). Taken together, it 
may be implied that accumbal DA is strongly associated with reward. It 
should be emphasized that increased DA levels in other areas are not 
always associated with reward; hence increased DA utilization in the 
prefrontal cortex is associated with foot shock, swim stress or 
conditioned fear (Le Moal and Simon, 1991; Westerink 1995). 
 
In addition to the rewarding properties of drugs, accumbal DA has 
been suggested to be involved in the expectation of reward. 
Anticipation of ethanol self-administration enhances the accumbal DA 
overflow in rats (Weiss et al, 1993; Gonzales and Weiss, 1998; Katner 
and Weiss, 1999; Melendez et al, 2002), an effect that is pronounced in 
alcohol-preferring rats (Katner et al, 1996). Additionally, it has been 
demonstrated that alcohol-associated cues activates the ventral 
striatum in abstinent high-risk drinkers and alcoholics (Braus et al, 
2001; Kareken et al, 2004). Similarly, in rats the firing of neurons in the 
N.Acc. increases during reward anticipation (Martin and Ono, 2000). 
Neuroleptics have been found to impair the response to a drug-
associated cue (Wise, 1996) and low doses of DA D2 receptor 
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antagonists reduce ethanol-seeking behaviour, but not ethanol 
consumption (Czachowski et al, 2001; Czachowski et al, 2002); thus 
raising the possibility for a role of DA in incentive motivational 
processes, such as drug-seeking behaviour. Interestingly, this accumbal 
DA overflow is thought to activate appropriate motor stimulation and 
motivation programs for reward-seeking behaviour and consumption 
(Engel and Carlsson, 1977; Wise and Bozarth, 1987, Wise, 1987; for 
review see Le Moal and Simon, 1991; Hodge et al, 1994; Hoshaw and 
Lewis, 2001). Conclusively, DA may be important in processes 
involved in ”wanting” (measured e.g. by voluntary intake or preference 
tests) (Berridge and Robinson, 1998) as well as in ”liking” (hedonic 
affective reaction measured by taste reactivity tests) (e.g. Volkow et al, 
1997; Drevets et al, 2001; Leyton et al, 2002; Martinez et al, 2003).  
 
It should also be emphasized that addictive drugs affect several other 
neurotransmitters, e.g. gamma-aminobutyric acid (GABA), 
acetylcholine (ACh), serotonin (5-HT), noradrenaline (NA) and 
opioids, and that DA alone will only explain some of the rewarding 
effects of addictive drugs (e.g. Engel et al, 1988; Engel et al, 1992; 
Little, 1999; Engel et al, 1999). The pharmacological properties of 
ethanol may also be mediated by peptides and hormones (Fig. 2) 
(Engel et al, 1999). 
 
Fig. 2. The “reward” profile of ethanol.  
Several different neurotransmitters, neuromodulators and individually related factors 
collectively orchestrate the rewarding profile of addictive drugs, e.g. ethanol. DA, 
dopamine; NA, noradrenaline; ACh, acetylcholine; 5-HT, serotonin; EAA, excitatory 
amino acids (Engel et al, 1992). 
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Natural rewards and dopamine 
The mesolimbic DA system can be activated by natural rewards such 
as sex (Mas et al, 1990; Pleim et al, 1990; Damsma et al, 1992), water 
(Roop et al, 2002) and food (even in non-starving animals) (Hernandez 
and Hoebel, 1988; Hernandez and Hoebel, 1990; Martel and Fantino, 
1996), thereby causing an increase in the extracellular concentration of 
accumbal DA (Yoshida et al, 1992; for review see Horvitz, 2000). 
However, drugs of abuse are three to five times more potent in their 
ability to stimulate accumbal DA release than natural rewards (Wise, 
2002). Interestingly, standard food increases the extracellular levels of 
DA in the core of N.Acc (Bassareo and Di Chiara, 1997; Bassareo and 
Di Chiara, 1999), whereas palatable food, such as salty snacks 
(Bassareo and Di Chiara, 1997), Fonzies (Tanda and Di Chiara, 1998) 
or chocolate (Bassareo et al, 2002) enhances the DA levels in N. Acc. 
shell. 
 
Since ensuring an adequate nutritional state is essential for the animal’s 
survival, it is most likely that several different neural systems driving 
feeding behaviour have been developed. The behaviours driving 
animals (and man) to work and to seek for food needs to be highly 
motivated and to some extent rewarding; thus implicating a role for the 
mesocorticolimbic DA system in food-seeking behaviour and food 
reward (for review see Saper et al, 2002). Interestingly, lesions of the 
DA reward system does not affect food intake per se, but reduces the 
willingness of the animal to engage in behavioural actions aimed at 
anticipation or searching for food (for review see Berridge, 1996). DA 
has therefore been proposed to play a role in incentive salience 
(“wanting”) such as food-seeking, rather than finding the sweet taste of 
sucrose (“liking”) rewarding (for review see Berridge and Robinson 
1998; Cannon and Palmiter 2003; Berridge 2004; Kringelbach 2004). In 
support of this hypothesis are findings associating ventral striatal DA 
release to the desire for food during presentation of palatable food 
stimuli in humans (Volkow et al, 2002) as well as with appetizing food 
(Beaver et al, 2006). Similarly, primates trained to associate a cue with a 
pleasurable experience (food), will show an increase in accumbal 
dopaminergic activity as a response to the cue and not to the food 
(Schultz, 2001). An in vivo voltametry study has further demonstrated 
that food-predicting cues increase firing of accumbal DA neurons 
(Roitman et al, 2004). Moreover, in rats DA transients in the ventral 
striatum are more frequent during brief conspecific introduction of a 
female than during copulation (Robinson et al, 2002). Further, the 
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activity of the DA neurons increases more potently before the 
potential delivery of an uncertain reward (related to gambling) than 
during gambling per se (Fiorillo et al, 2003).  
 
The food-induced DA overflow in the N.Acc. shell is blunted at 
repeated exposures to palatable foods (Bassareo and Di Chiara, 1997; 
Bassareo et al, 2002), implying an important role for novelty in reward 
responses (Spanagel and Weiss, 1999). Interestingly, the increased DA 
levels in N.Acc. shell is not blunted following subsequent 
administrations of addictive drugs (Di Chiara, 2002) or following 
repeated exposures to palatable foods in the case of disrupted eating 
behaviours (Di Chiara, 2005; Rada et al, 2005). Furthermore, the 
constant challenge to the mesolimbic DA system by the excessive use 
of rewards e.g. addictive drugs or changed eating behaviour, might 
cause neuroadaptive changes. Accordingly, a decreased number of DA 
D2- receptors has been demonstrated in cocaine (receptors that 
recover following a drug-free interval) (Volkow et al, 1990; Volkow et 
al, 1993) and methamphetamine abusers (Volkow et al, 2001) as well as 
in opiate (Wang et al, 1997) and ethanol dependent individuals using 
PET studies (Volkow et al, 1996) or using neuroendocrine tests 
(Balldin et al, 1992). Comparatively to drug addiction, a lower density 
of DA D2- receptors have been demonstrated in patients suffering 
from compulsive overeating (Volkow et al, 2003a, Wang et al, 2004a). 
Furthermore, ethanol withdrawal causes a reduction in the firing of 
DA neurons in the VTA as well as in accumbal DA levels (Diana et al, 
1992; Rossetti et al, 1992). The use of addictive drugs or overeating has 
been suggested to reflect a compensatory behaviour for this impaired 
DA transmission and those individuals who do not show recovery to 
the normal number of DA D2- receptors at withdrawal are more likely 
to relapse. Taken together, a role for accumbal DA release in the 
hedonic feeling of incentives, natural as well as artificial, and in 
motivated behaviours such as drug- and food-seeking behaviour may 
be implicated.  
 
The major afferents that modulate the activity 
of dopamine neurons in the ventral tegmental 
area 
Accumbal DA release is modulated by various afferents to the VTA 
(e.g. Kalivas, 1993; Wise, 2002;), such as the glutamatergic input from 
precortical areas, which mainly has been shown to be tonic, excitatory 
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and N-methyl-D-aspartic acid (NMDA)-dependent (Schilström et al, 
1998a: for review see Kitai et al, 1999; Carr and Sesack, 2000; Sesack et 
al, 2003). Additional glutamatergic afferents to the VTA originate in 
the lateral hypothalamus (Rosin et al, 2003), bed nucleus of stria 
terminalis (Georges and Aston-Jones, 2002) and the superior coliculus 
(Geisler and Zahm, 2005). The GABAergic input, e.g. from the N.Acc. 
shell and medial part of ventral pallidum, (Conrad and Pfaff, 1976; 
Walaas and Fonnum, 1980; Kalivas et al, 1993) and the GABAergic 
interneurons within the VTA modulate the activity of ventral 
tegmental dopaminergic neurons (Sesack and Pickel, 1995). Activation 
of the GABAergic neurons in the VTA inhibits the release of 
accumbal DA (see e.g. Koob, 1992b). Additionally, these striatal 
projections may co-contain peptides such as substance P and 
dynorphins (Fallon et al, 1985; Lu et al, 1998). 5-HT afferents from the 
dorsal and medial raphe (Parent et al, 1981; Herve et al, 1987) and the 
hypothalamic opioidic provide input via the ventral tegmental 
GABAergic interneurons (Sesack and Pickel, 1995; Greenwell et al, 
2002) have also been demonstrated to modulate the activity of the DA 
neurons in VTA. The activity of dopaminergic neurons in the VTA 
can also be modulated by noradrenergic afferents from the locus 
coeruleus (Grenhoff et al, 1993). Moreover, the orexin containing 
projections from lateral hypothalamus to VTA have been suggested to 
regulate ventral tegmental DA neurons (Semba and Fibiger, 1992; 
Fadel and Deutch, 2002; Korotkova et al, 2003). Additionally, the 
GABAergic as well as the excitatory cholinergic and glutamatergic 
input from the mesopontine area appears to have an important 
modulatory role (Clements and Grant, 1990; Clements et al, 1991; 
Semba and Fibiger, 1992; Futami et al, 1995; for review see Kitai et al, 
1999; Larsson et al, 2005) (Fig. 3).  
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Fig. 3. The major afferents that modulate the activity of the dopaminergic 
neurons in the ventral tegmental area (VTA). 
ACh, acetylcholine; GABA, gamma-aminobutyric acid; NA, noradrenaline; 5-HT, 
serotonin, MC; melanocortins; N.Acc, nucleus accumbens, LDTg, laterodorsal 
tegmental area. 
 
Cholinergic regulation of the ventral tegmental area 
Cholinergic neurons are widely distributed throughout the brain 
(Butcher and Woolf, 2003; Woolf, 1991) and have been suggested to 
play important roles in cognitive functions such as learning (Fine et al, 
1997), memory (Hasselmo et al, 1992) and attention (Bucci et al, 1998). 
Interestingly, cholinergic neurons have been identified in the 
mesopontine area, i.e. the pedunculopontine tegmental area (PPTg) 
and laterodorsal tegmental area (LDTg). These neurons project to 
various brain regions, such as the thalamus, hypothalamus, basal 
forebrain, substantia nigra and medial limbic cortex (Mesulam et al, 
1983). Additionally, the cholinergic neurons in the mesopontine area 
provide the only known cholinergic projections to the VTA (Butcher 
and Woolf, 2003). Specifically, the cholinergic input to the VTA, 
originates primarily in the LDTg, whereas the PPTg mainly projects to 
substantia nigra (Berninato and Spencer, 1987; Clarke et al, 1987; 
Futami et al 1995; Oakman et al, 1995; Blaha et al, 1996a; for review 
see Winn et al, 1997). The LDTg has been suggested to regulate the 
activity of ventral tegmental DA neurons projecting to the ventral 
striatum (i.e. accumbal DA) (Forster and Blaha, 2000b; Forster et al, 
2001; Forster and Blaha, 2003), via activation of ventral tegmental 
nAChR, muscarinic acetylcholine receptors (mAChR) as well as 
glutamatergic receptors (Blaha et al, 1996a; for review see Winn et al, 
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1997; Forster and Blaha, 2000b; Forster and Blaha, 2003). Similarly, 
activation of nAChRs, in particular in the ventral tegmental area, have 
been found to increase DA in the N.Acc. (Clarke et al, 1988; Mifsud et 
al, 1989; Benwall and Balfour, 1992; Nisell et al, 1994).  The 
cholinergic neurons originating in the PPTg regulate the activity of 
dorsal striatum (for review see Winn et al 1997; Forster and Blaha, 
2000a; Forster and Blaha, 2003). However, it is unlikely that these 
relationships are wholly exclusive, as cholinergic projections from the 
PPTg, preferably the medial part, to the VTA have been identified 
(Jackson and Crossman, 1983; Fujimoto et al, 1990; Yeomans et al, 
1993; Oakman et al, 1995; for review see Laviolette and van der Kooy, 
2004).  
 
The cholinergic input to the VTA has previously been assumed to 
involve regulation of the GABAergic, rather than dopaminergic 
neurons (Garzone et al, 1999; Fiorillo and Williams, 2000). However, 
lately it has been shown that the cholinergic drive from the LDTg 
innervates the dopaminergic, rather than the GABAergic 
mesoaccumbal neurons in the VTA (Omelchenko and Sesack, 2005; 
Omelchenko and Sesack, 2006). Our research group has denominated 
the cholinergic projection, preferably from the LDTg, together with 
the mesolimbic DA system the cholinergic-dopaminergic reward link 
(Fig. 4). 
 
 
Fig. 4. The cholinergic-dopaminergic reward link. 
This link is composed of the cholinergic projection from the laterodorsal tegmental 
area (LDTg) to the ventral tegmental area (VTA) and the mesolimbic dopamine (DA) 
system projecting from the VTA to the nucleus accumbens (N.Acc.). Activation of the 
LDTg causes a release of acetylcholine (ACh) in the VTA which by interactions with 
nicotinic ACh receptors (nAChR) and/or muscarinic ACh receptors (mAChR) 
stimulates the mesolimbic DA system causing a release of DA in N.Acc.. 
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The cholinergic-dopaminergic reward link 
It is assumed that the mesopontine cholinergic projection, at least in 
part, constitute an excitatory input to the mesoaccumbal dopaminergic 
neurons; thus a ventral tegmental release of ACh causes an increase in 
accumbal DA (Blaha et al, 1996a; for review see Winn et al, 1997; 
Forster and Blaha, 2000b; Forster et al, 2001; Forster and Blaha, 2003; 
Larsson et al, 2005). The cholinergic projections via mAChRs exert a 
tonic excitatory influence on the dopaminergic neurons in the VTA 
(Yeomans et al, 1985; Kofman and Yeomans, 1989; Kofman et al, 
1990; Yeomans and Biptista, 1997). Moreover, since inhibition of 
nAChRs in the VTA does neither affect locomotor activity nor 
accumbal DA overflow per se, it has been suggested that the ventral 
tegmental nAChRs are involved in phasic rather than tonic influence 
on the mesolimbic DA system (Westerink et al, 1996; Ericson et al, 
1998; Grillner and Svensson, 2000; Larsson et al 2002; Larsson et al, 
2004).  
 
Involvement of cholinergic neurons in drug-induced as well as natural 
reward has been implied (vide infra). Infusion of a cholinergic agonist 
into the VTA increased the extracellular DA levels in the N.Acc. 
(Westerink et al, 1996) and has rewarding effects as measured by a 
conditioned place preference task (Yeomans et al, 1985). Furthermore, 
it has been shown that hypothalamic self-stimulation, food or water 
intake (Rada et al, 2000) or electrical self-stimulation of the medial 
forebrain bundle (Nakahara et al, 2001) increases the extracellular 
levels of ACh in the VTA. In addition, lesion of the PPTg decreases 
nicotine and cocaine self-administration (Lanca et al, 2000; Corrigall et 
al, 2002) and inhibits the motivational effects of opiates (Bechara and 
van der Kooy, 1992). Similarly, lesions of the PPTg attenuates the 
intake of saccharin and water in rats (Stefurak and van der Kooy, 
1994), blocks the rewarding properties of food (Bechara and van der 
Kooy, 1992) and impairs copulation in naïve male rats (Kippin and van 
der Kooy, 2003). Lesioning the medial PPTg, the part of PPTg 
projecting to the VTA, blocks conditioned place preference for 
morphine and amphetamine (Bechara and van der Kooy, 1989). 
Furthermore, it has been shown that ethanol intake in high ethanol-
preferring rats causes a concomitant, and almost time-locked, increase 
in ventral tegmental ACh and accumbal DA (Larsson et al, 2005). 
Hence, a role for the cholinergic-dopaminergic reward link in natural 
as well as drug-induced reinforcement may be suggested. 
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Afferents modulating the activity of the mesopontine 
cholinergic neurons 
It has been shown that different inputs to the mesopontine area 
modulate the activity of cholinergic neurons. The major origins for the 
mesopontine afferents are the substantia nigra (e.g. Beckstead et al, 
1979; Semba and Fibiger, 1992), the subthalamic nucleus (e.g. Granata 
and Kitai, 1989) and the globus pallidus (e.g. Kim et al, 1976). 
Additionally, non-dopaminergic projections, presumably GABAergic, 
from the VTA and N.Acc. to the mesopontine area have been 
identified (Walaas and Fonnum, 1980; Swanson, 1982; Goldsmith and 
van der Kooy, 1988; Semba and Fibiger, 1992).  
  
Nicotinic acetylcholine receptors 
ACh exerts its effects through both nAChRs and mAChRs. These 
receptors were classified by Sir Henry Dale (for review see Gaudenz 
Waser, 1986) and it has been shown that the expression levels of 
nAChRs are lower then those of mAChRs (Wada et al, 1989; Sargent, 
2000). There are five different subtypes of the mAChRs, m1-m5, and 
they belong to the super-family of G-protein coupled receptors. The 
mAChRs, coupled to second messenger systems, mediate the slow 
effects of ACh, whereas the nAChRs, as ligand-gated ion channels, 
mediate the fast synaptic transmission of the neurotransmitter. The 
nAChRs, together with the GABAA, glycine and 5-HT3 receptors, 
belong to the gene super-family of ligand-gated ion channels (e.g. 
McGehee and Role, 1995; Sieghart and Sperk, 2002; Lynch, 2004). The 
neuromuscular nAChRs were described by Langley (1907), whereas the 
neuronal nAChRs were not identified until decades later (Caulfield and 
Higgins, 1983; Clarke et al, 1984; Clarke and Pert, 1985; Clarke et al, 
1985; Collins et al, 1996). Both pre-synaptic and post-synaptic nAChRs 
have been show to be widely distributed in the brain (Clarke and Pert, 
1985; Lindstöm, 1997). An important modulatory role for pre-synaptic 
nAChRs, located on e.g. glutamatergic, GABAergic and noradrenergic 
neurons, have been demonstrated (McGehee and Role, 1995; 
Wonnacott, 1997), although a similar role has also been assigned to 
post-synaptic nAChRs (Ullian et al, 1997). Several different brain 
functions such as cognition, learning, memory, arousal and motor 
function have been linked to the neuronal nAChRs (Arneric and 
Brioni, 1999; Lukas et al, 1999; Paterson and Nordberg, 2000; Levin, 
2002).  
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Subtypes of the nicotinic acetylcholine receptor 
The nAChR consist of five subunits that form a pentameric ion-
channel. All subunits have a similar structure, i.e. two hydrophilic and 
four transmembranic domains (M1-M4). The M2 domains from each 
subunit form the wall of the central aqueous pore (Cartaud et al, 1973), 
which allows the cations Na+, K+ and Ca2+ to flux through the 
receptor (Changeux et al, 1998). The subunits expressed in the central 
nervous system (CNS) are the ?2-?10 and ?2-?4 (Lukas et al, 1999). 
More specifically, the mRNA expression of the ?2-?7 and ?2-?4 
subunits in VTA have been identified with reverse transcriptase-
polymerase chain reaction (Charpantier et al, 1998) and the ?3-?6 and 
?2-?3 subunits in VTA with in situ hybridization (Lena and Changeux, 
1997; Le Novere et al, 2002). The subunits of ?3-?7 and ?2-?4 have 
been localized on dopaminergic cell bodies and on non-dopaminergic 
neurons in the VTA (Klink et al, 2001). The different subunit 
combinations form a large variety of nAChRs, i.e. subtypes, either as 
heteromeric or homomeric receptors (Fig. 5). The subtypes have 
different distribution patterns and may in all probability have various 
functional roles (for review see Nicke et al, 2004). Interestingly, the 
different nAChR subtypes are characterized by significant differences 
in properties such as ligand pharmacology, activation and 
desensitization kinetics and cation permeability (Chavez-Noriega et al, 
1997).  
 
 
Fig. 5. The pentameric nicotinic acetylcholine receptor (nAChR). 
The nAChR can be a homeomeric or heteromeric receptor, and these have different 
functional roles and different distribution pattern. 
 
 33 
The homomeric nAChRs are composed of the ?7, ?8 or ?9 subunits 
(Arneric and Brioni, 1999). The heteromeric subtypes of the nAChRs 
are formed from the ?2-?6 and ?2-?4 subunits (Nelson et al, 2003). 
The ?9 and ?10 subunits have not been found in the VTA and the ?8 
subunit has only been found in chick.  
Interestingly, not all subunits can be combined and form functional 
receptors (for review see Nicke et al, 2004). More specifically, it has 
been shown in Xenopus oocytes or mammalian cell lines that the 
subunits ?2, ?3 and ?4 all can form functional subtypes with both the 
?2 and the ?4 subunits. Contrarily, the ?6 subunit can only form 
functional receptors with the ?4 but not with the ?2 subunit (Chavez-
Noriega et al, 1997; Stauderman et al, 1998; Lukas et al, 1999; Chavez-
Noriega et al, 2000; Kuryatov et al, 2000; Dowell et al, 2003). The ?5 
and ?3 subunits are structural subunits and can therefore be used to 
form more complex nAChRs, however, since they lack amino acid 
residues important for agonist binding they cannot be involved in the 
formation of the binding site (Ramirez-Latorre et al, 1996; Boorman et 
al, 2003). The asterisk used in the receptor nomenclature indicates that 
other subunits might be present in the receptor complex. 
 
The most common subunits in the CNS are the ?4, ?2 and ?7, which 
are widely distributed in the brain (Clarke et al, 1985; Wada et al, 1989; 
Séguéla et al, 1993; for review see Lindstöm et al, 1995; Paterson and 
Nordberg, 2000). In fact, approximately 90% of all nAChRs in the 
CNS have been identified as the ?4?2* receptor, known as the high-
affinity nicotine binding site, and the second most common nAChRs is 
the ?7* receptor. The expression of other subtypes is more limited 
(Wada et al, 1989; Flores et al, 1992; Séguéla et al, 1993). However, 
there is no democracy in the brain and less common subtypes can have 
essential functional roles.  
 
Selective antagonists for the different subunits of the 
nicotinic acetylcholine receptor 
The functional importance of the different subunits can be studied by 
using e.g. subtype-specific nicotinic agonists/antagonists and gene-
manipulated mice. The availability of selective pharmacological tools 
(that can distinguish between different nAChR subtypes) is still limited.  
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Fig. 6. The subunit selectivity of different nicotinic antagonists used in the 
present thesis.  
Mecamylamine (MEC); Dihydro-?-erythroidine (DH?E); methyllycaconitine (MLA); 
?-Conotoxin MII (?CtxMII); ?-Conotoxin PIA-analogue (?CtxPIA-analogue). 
 
Several different nicotinic antagonists were used in the present thesis 
(Fig. 6). Mecamylamine (MEC) is an unselective negative allosteric 
modulator of the nAChR and binds in the aquatic pore of the receptor. 
MEC has previously been used clinically as an antihypertensive drug 
but was removed from the market due to unpleasant side effects such 
as dry mouth, constipation and ortostatic hypotension (Young et al, 
2001). MEC may act as a non-selective, non-competitive antagonist of 
NMDA receptors (O’Dell and Christensen, 1988; Papke et al, 2001). 
Dihydro-?-erythroidine (DH?E) is a rather selective competitive 
antagonist for the ?4?2* subunits (Alkodon and Alberquerque, 1993; 
Dwoskin and Crooks, 2001; Khiroug et al, 2004). However, at higher 
doses DH?E displays affinity for numerous other subunits than (see 
e.g. Buisson et al, 1996). The plant alkaloid, methyllycaconitine (MLA) 
has experimentally been shown to be selective for the ?7* subunits 
(Macallan et al, 1988; Ward et al, 1990; Alkondon et al, 1992; 
Wonnacott et al, 1993; Holladay et al, 1997; Davies et al, 1999) as well 
as to display a low affinity for the ?6 * subtype (Vailati et al, 1999). 
Nevertheless, it was recently shown that MLA, especially in higher 
doses, blocks the ?3* and/or ?3?2?3* subunits (Klink et al, 2001; 
Mogg et al, 2002; Salminen et al, 2004). Both DH?E (Bowman and 
Rand, 1980) and MLA (Turek et al, 1995) have been shown to pass the 
blood brain barrier (BBB). ?-Conotoxin MII (?CtxMII) is a venom 
from a predatory marine cone shell, Conus magus (McIntosh et al, 1999). 
It is a 16 amino acid peptide with two disulfide bridges that together 
form a complex three-dimensional structure and is proposed to be a 
selective competitive antagonist for the ?3?2* (Cartier et al, 1996; 
Grady et al, 2001), ?3* (Cui et al, 2003) and ?6 * (Vailati et al, 1999; 
Champtiaux et al, 2002) containing nAChRs. ?-Conotoxin PIA 
(?CtxPIA), another venomous peptide from a marine cone shell, Conus 
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purpurascens, is composed of 18 amino acids and two disulfide bridges, 
together forming a complex three-dimensional structure. The amino 
acid sequence is quite homologous compared to ?CtxMII, however, 
the nAChR subunit selectivity is different. It has been reported that 
?CtxPIA shows a significantly higher affinity for the ?6 * subunit 
rather than the ?3?2* and ?3* subunits (Dowell et al, 2003). Both 
?CtxMII and ?CtxPIA belong to the super-family of 4/7 ?-
conotoxins, due to the positions of the disulfide bridges. The nAChR 
subunit selectivity of 4/7 ?-conotoxins has been reported to reside to 
the central and the C-terminal part of the peptide, whereas the N-
terminal amino acids appear to be of less importance (McIntosh et al, 
1999; Arias and Blanton, 2000; Dutertre and Lewis, 2004; Everhart et 
al, 2004; Dutertre et al, 2005). Specifically, the bulky charged N-
terminal protrusion of ?CtxPIA has been suggested to be of less 
importance for its interaction with the ?6 subunit of the nAChR (Chi 
et al, 2005). The subunit selectivity of the ?CtxPIA-analogue is 
therefore assumed to be similar to the one for ?CtxPIA (Fig. 7). Due 
to the size of the peptides, such as those used in the present thesis, it is 
unlikely that they pass the BBB. 
 
 
Fig. 7. Amino acid sequence and nAChR subunit selectivity of three different 
?-conotoxins. 
?-Conotoxin MII (?CtxMII); ?-Conotoxin PIA (?CtxPIA); ?-Conotoxin PIA 
(?CtxPIA-analogue) 
 
Functional roles for the different subunits of the 
nicotinic acetylcholine receptor 
The different subtypes of the nAChRs show a regional distribution, 
regulate various physiological processes and are associated with a 
number of brain disorders e.g. ?4?2* and epilepsy or ?7* and 
schizophrenia (for review see Picciotto et al, 2001). It has been 
reported that the central nAChRs, especially those located in the VTA, 
play a role in mediating the accumbal DA enhancing, stimulatory and 
rewarding properties of nicotine (Clarke et al, 1988; Wonnacott et al, 
1990; Corrigall et al, 1994; Di Chiara, 2000) and ethanol (Blomqvist et 
 36 
al, 1997; Larsson et al, 2002; Ericsson et al, 2003) as well as in food-
induced accumbal DA overflow (Schilström et al, 1998b). It may be 
hypothesized that certain subtypes of the nAChRs are involved in 
mediating the reinforcing properties of addictive drugs, e.g. nicotine or 
ethanol, as well as of natural rewards. Thus, results from genetically 
modified mice, suggesting that the ?4 and ?2 subunits appear to be 
involved in the development of nicotine addiction (Picciotto et al, 
1998; Tapper et al, 2004). Additionally, DH?E, antagonizes nicotine-
induced hypomotility in mice (Damaj et al, 1995) and shifts the dose-
response curve for the discriminative stimulus effect of nicotine to the 
right (Gommans et al, 2000). Similarly, DH?E blocks nicotine-induced 
locomotor stimulation (Stolerman et al, 1997), nicotine-induced 
accumbal DA overflow as well as nicotine self-administration (e.g. 
Alkondon and Alberquerque, 1993; Corrigall et al, 1994; Grillner and 
Svensson, 2000; Dwoskin and Crooks, 2001; Larsson et al, 2002; 
Ericsson et al 2003; Khiroug et al, 2004). Furthermore, MLA blocks 
nicotine-induced accumbal DA overflow (Schilström et al, 1998b; 
Larsson et al, 2002), suggesting that the ?4?2* and ?7* subunits are 
important for behavioural and neurochemical effects of nicotine. In 
addition, the ?6* subunit has been suggested to play an important role 
in nicotine-induced locomotor stimulation (Le Novere et al, 1996) and 
the ?6?2?3* subunits have been implicated in mediation of the DA 
enhancing properties of nicotine (Champtiaux et al, 2002). 
Furthermore, administration of MLA into the VTA attenuates the 
food-induced accumbal DA overflow (Schilström et al, 1998b), 
implying a role for the ?7 subunit, in food related reward. Contrarily, 
DH?E does neither modify ethanol self-administration (Lê et al, 2000), 
nor ethanol-induced accumbal DA overflow in rats (Ericson et al, 
2003). In a recent study systemic administration of either DH?E or 
MLA had no effect on ethanol-induced locomotor activity and 
dopamine overflow in N.Acc. in mice (Larsson et al, 2002). 
Furthermore, administration of ?CtxMII into the VTA antagonizes 
ethanol-induced locomotor stimulation and accumbal DA overflow in 
mice as well as ethanol intake and preference in mice and rats (Larsson 
et al, 2004). Taken together, this indicate that ?3?2*, ?3* and/or ?6*, 
rather than the ?4?2*, and/or ?7*, subunits of the nAChR, are 
involved in mediating these neurochemical and behavioural effects of 
ethanol (Fig. 8). 
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Fig. 8. The ?3?2*, ?3* and/or ?6*, rather than the ?4?2* or ?7*, subtypes of the 
nicotinic acetylcholine receptor appear to be involved in mediating the 
stimulatory and dopamine-enhancing effects of ethanol. 
 
Ethanol 
It has been known since the 1940s that rodents voluntarily drink 
ethanol in a laboratory setting (Richter and Campbell, 1940). This 
drinking behaviour has thereafter been observed in freely living 
animals, who intoxicate themselves by eating rotten fruit (for review 
see Spanagel, 2000). 
 
Ethanol is a small molecule with both lipophilic and hydrophilic 
characteristics and when ingested, ethanol spreads quickly and passes 
the BBB into the CNS (e.g. Barry, 1991). Ethanol has a complex and 
diverse pharmacological profile including effects such as euphoria, 
locomotor stimulation, sedation, anxiolysis and muscle relaxation. In 
addition, ethanol is a low potent drug, i.e. several grams are needed for 
an effect.  
 
Ethanol and ligand-gated ion channels 
Ethanol was previously believed to produce its effects via a direct 
action on the cell membrane’s lipid bi-layer (Meyer, 1899). However, 
this theory has been revised and a large body of evidence indicates that 
ethanol, in rather small doses, interacts directly with ligand-gated ion 
channels such as 5-HT3, GABAA, glycine, NMDA, and nACh 
receptors (Narahashi et al, 1991; Grant, 1994; Lovinger, 1997; 
Lovinger, 1999; Narahashi et al 2001; for review see Larsson and 
Engel, 2004), as well as Ca2+ channels (Davies, 2003). Ethanol can 
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either stimulate or inhibit these receptors, depending on the receptor 
type or subtype (Harris, 1999). 
 
In vitro studies have shown that ethanol might act as a co-agonist for 
the 5-HT3 receptor (Lovinger and White, 1991; Machu and Harris, 
1994; Jenkins et al, 1996) and that ethanol potentiates the action of 5-
HT on this receptor (Lovinger and Zhou, 1994).  Additionally, ethanol 
augments the effects of GABA on the GABAA receptor by increasing 
the influx of Cl-; thus it has been suggested that ethanol acts as an 
allosteric modulator of the GABAA receptor (Suzdak et al, 1986). The 
interaction between ethanol and GABAA receptors may cause 
hypnosis, sedation, anxiolysis and muscle relaxation (Liljequist and 
Engel, 1982; Liljequist and Engel, 1983). Furthermore, ethanol, glycine 
and other glycine agonists act synergistically at the strychnine-sensitive 
glycine receptors (Mascia et al, 1996). Ethanol acutely inhibits the 
NMDA glutamate receptor (Hoffman et al, 1989; Lovinger et al, 1989). 
Interestingly, clinical and pre-clinical studies show that manipulation of 
these systems affects the ethanol intake and therefore might be 
efficient as additional pharmaceuticals for treatment of alcoholism (e.g. 
Engel, 1977; Blaha et al, 1996b; LeMarquand et al, 1994a; LeMarquand 
et al, 1994b; Johnson et al, 2000; Koob et al, 2002; Addolorato et al, 
2002; Molander et al, 2005) 
 
The first evidence for a possible interaction between ethanol and 
nAChRs were results from our group showing that chronic ethanol 
consumption produces changes in the Bmax for 3[H]-nicotine in 
different regions of the rat brain (Yoshida et al, 1982). Additionally, 
long-term ethanol treatment in mice increases 3[H]-nicotine binding in 
the thalamus (Booker and Collins, 1997). Given that ethanol can 
stabilize the open state of the Torpedo nAChR (Wu et al, 1994; 
Forman and Zhou, 1999), increase the agonist affinity for this receptor 
(Forman et al, 1989) and enhance the response to nicotine (Marszalec 
et al, 1999), it may be suggested that ethanol acts as a co-agonist with 
ACh on the nAChRs.  
 
In subsequent studies it has been found that ethanol intake and 
preference as well as ethanol-induced locomotor stimulation and 
accumbal DA overflow may involve central nAChR, especially those 
located in the VTA (Blomqvist et al, 1992; Blomqvist et al, 1993; 
Blomqvist et al, 1997; Ericsson et al, 1998; Nadal et al, 1998; Lê et al, 
2000; Larsson et al, 2002; Tizabi et al, 2002; Ericson et al, 2003; 
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Larsson et al, 2004). More specifically, ?CtxMII-sensitive, e.g. ?3?2*, 
?3* and/or ?6* subtypes of the nAChR in the VTA, have been 
demonstrated to be involved in mediating the locomotor stimulatory, 
rewarding and DA enhancing effects of ethanol (see Functional roles for 
the different subunits of the nicotinic acetylcholine receptor). 
 
Neurochemical overlap between the reward 
systems and those regulating energy balance 
Several studies have suggested that there is a neurochemical overlap 
between the reward systems and the systems regulating energy 
homeostasis (for reviews see DiLeone et al, 2003; Thiele et al, 2003; 
Thiele et al, 2004), implicating especially peptides such as leptin, 
orexin, neuropeptide Y (NPY) and galanin. 
 
Relation between food and substance abuse 
The interconnection between neural networks involved in feeding and 
drug reward is further demonstrated by studies showing that food 
deprivation enhances the rewarding properties of addictive drugs 
including heroin, amphetamine and cocaine (Carroll et al, 1979; Cabeza 
de Vaca and Carr, 1998; Stuber et al, 2002) and increases drug craving 
in humans (for review see Grigson, 2002). Furthermore, food 
restriction potentiates the threshold-lowering effect on self-stimulation 
in the lateral hypothalamus exerted by drugs (Cabeza de Vaca and 
Carr, 1998), augments the reinforcing value of electrical self-
stimulation of the brain reward system (Fulton et al, 2000) and 
increases the cocaine-induced conditioned place preference and 
locomotor stimulation (Bell et al, 1997). This may be related to altered 
levels of orexigenic/anorexigenic peptides, even though an influence 
of other causes such as stress cannot be excluded. Moreover, high-
ethanol preferring rats as well as alcoholics show a high preference for 
sweets (Kampov-Polevoy et al, 1999; for review see Grigson, 2002) 
and there is a co-morbidity between eating disorders and drug or 
alcohol abuse (Wolfe and Maisto, 2000). Although similarities between 
natural and drug-induced reward may be assumed, it has to be 
emphasized that food and drugs partly activate different neurons in the 
VTA (for review see Grigson, 2002).  
 
 40 
The orexigenic/anorexigenic peptides and their effects 
on reward and drugs of abuse 
Several peptides, such as ghrelin, NPY, galanin, orexin and melanin-
concentrating hormone (MCH) stimulate feeding whereas other 
peptides including leptin, melanocortins (MC), cholecystokinin and 
corticotrophin-releasing factor, inhibit food intake (for review see 
Arora and Anubhuti, 2006). Additionally, there is an increasing body of 
evidence indicating that these peptides also act on the reward systems 
and have a role in addictive behaviours, such as drug addiction (vide 
infra). 
 
Centrally acting NPY has DA enhancing properties in the N.Acc. 
(Salin et al, 1990) and has been found to reduces voluntary ethanol 
consumption in rodents, especially in those bread to consume ethanol 
(for review see Kiefer and Wiedemann, 2004; Thorsell et al, 2006). 
Additionally, MCH acts centrally to increase alcohol or sucrose intake 
in rats (Duncan et al, 2005). A microinjection of orexin into the VTA 
of rats increases the DA levels in the N.Acc. (Narita et al, 2006). 
Further, central infusion of orexin causes a dose-related reinstatement 
of cocaine seeking without changing cocaine intake (Boutrel et al, 
2005) and reinstates morphine seeking (Harris et al, 2005). Moreover, 
orexin has in situations of nutritional depletion been suggested to 
stimulate arousal and motivation to reinforce food-seeking/feeding 
pathways and thereby ensure survival (for review see Sakurai, 2005). 
Hypothalamic administration of galanin increases DA and decreases 
ACh levels in the N.Acc. (Rada et al, 1998), possibly mediated via 
galanin receptors in the VTA (Hawas and Picciotto, 2004). Central 
administration of galanin has also been seen to increase ethanol intake 
in rats (Lewis et al, 2004; Rada et al, 2004a). The anorexigenic MC 
peptides decrease voluntary alcohol drinking in rats (Ploj et al, 2002). 
Furthermore, leptin into the lateral ventricle can suppress the basal 
levels of accumbal DA as well as the feeding-induced increase in 
accumbal DA (Krugel et al, 2003). Elevated leptin levels have been 
demonstrated in male alcoholics (Nicolas et al, 2001) and high ethanol-
preferring mice (Obradovic and Meadows, 2002) and have been 
associated with alcohol craving during withdrawal (Kraus et al, 2005), 
effects tentatively mediated via leptin receptors expressed in the VTA 
(Figlewicz et al, 2003). Similarly, inhibition of leptin decreases ethanol 
preference in mice (Blednov et al, 2004) and leptin increases the 
ethanol intake (Kiefer et al, 2001) as well as enhances the motivation 
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for alcohol consumption in habituated mice after alcohol withdrawal 
(Kiefer et al, 2005). Nevertheless, the present thesis is focused on 
another energy balance regulating peptide, ghrelin. 
 
Ghrelin 
Ghrelin was isolated from rat stomach and was identified as the first 
endogenous ligand for the growth hormone secretagogue receptor 
(GHSR). It was given the name ghrelin; “ghre” as the etymological 
root for growth and the suffixes “GH” and “relin” as an abbreviation 
for “growth-hormone release”, a characteristic effect of ghrelin 
(Kojima et al, 1999; Hosoda et al, 2000b; Casanueva and Diéguez, 
2002; Schmid et al, 2005). Ghrelin is highly conserved among different 
species, particularly among mammals (Kojima et al, 1999; Kaiya et al, 
2001; Saito et al, 2002; Hosoda et al, 2003; Kaiya et al, 2003; van der 
Lely et al, 2004; Kojima and Kangawa, 2005). It is a twenty-eight 
amino acid peptide acylated at the third serine position, which is 
essential for the activity of the peptide (Kojima et al, 1999). The 
acylated ghrelin, used in the present thesis, has been recognized as an 
orexigenic peptide (Date et al, 2000; Hosoda et al, 2000a), whereas the 
des-acyl ghrelins mainly have different or opposite effects to the 
acylated forms (Asakawa et al, 2005; Chen et al 2005a, Chen et al, 
2005b; Ukkola, 2005).  
 
Ghrelin is mainly produced in and secreted from the stomach (Kojima 
et al, 1999; Date et al, 2000; Sakata et al, 2002), however, smaller 
amounts are also produced in other gastrointestinal segments (Hosoda 
et al, 2000a), in peripheral tissues such as the pancreas, kidney, pituitary 
and spleen (Gnanapavan et al, 2002; for review see Korbonits and 
Grossman, 2004) and in the brain (Cowley et al, 2003; Mondal et al, 
2005; Sato et al, 2005). Based on the assumption that the effects of 
growth hormone secretagouges (GHS; ghrelin mimetics) on food 
intake and GH release are thought to be mediated via central 
mechanism (Lall et al, 2001; for review see Smith, 2005), it was 
suggested that peripherally produced ghrelin also may have central 
effects. However, bioactive ghrelin is foremost known to be 
transported from the brain across the BBB, rather than the opposite 
direction (Banks et al, 2002). On the other hand, ghrelin containing 
cells have been identified in the hypothalamus (Lu et al, 2001) and 
ghrelin mRNA has been found adjacent to the third ventricle in the 
brain (Cowley et al, 2003), the arcuate nucleus (Mondal et al, 2005) as 
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well as in the hypothalamus (Sato et al, 2005), implicating that centrally 
produced ghrelin may be of importance.  
 
Two types of the G-protein coupled GHSRs have been identified: 
GHSR-1A and GHSR-1B. GHSR-1A is activated by ghrelin and GHS, 
whereas GHSR-1B is not. The expression of mRNA for GHSR-1A in 
the human brain appears to resemble that of the rat brain, where the 
main expression is observed within different hypothalamic nuclei, the 
arcuate nucleus among others. However, the expression of GHSR-1A 
is not restricted to the hypothalamus. It has been identified e.g. in the 
pituitary, hippocampus, VTA and the LDTg (Howard et al, 1996; 
Guan et al, 1997). Interestingly, the two latter nuclei have central roles 
in the endogenous reward systems (see The mesocorticolimbic dopamine 
system). In addition to the CNS mRNA for ghrelin and its receptor is 
widely distributed within the human body, e.g. stomach, pancreas, heart 
and kidney (Howard et al, 1996; Gnanapavan et al, 2002; Gaytan et al, 
2004; Sun et al, 2004), suggesting that ghrelin has multiple 
physiological functions. More specifically, it has been demonstrated 
that ghrelin is involved in mediation of sleep, memory and anxiety-like 
behaviour in rats (for reviews see Einstein and Greenberg, 2003; van 
der Lely et al, 2004; Ghigo et al, 2005). 
 
Role of ghrelin in energy homeostasis 
It may be suggested that ghrelin plays a role in appetite and meal 
initiation as well as in consummatory feeding behaviours. Numerous 
studies have demonstrated that central as well as peripheral 
administration of ghrelin increases food intake in rats and humans 
(Tschöp et al, 2000; Nakazato et al, 2001; Wren et al, 2001a; Wren et 
al, 2001b). Furthermore, chronic intracerebroventricular (icv) 
injections of ghrelin increase cumulative food intake in mice 
(Theander-Carrillo et al, 2006). The role of ghrelin in feeding is further 
supported by studies demonstrating that anti-ghrelin antibodies or 
GHSR antagonists suppress dark phase feeding as well as starvation-
induced food intake (Nakazato et al, 2001; Asakawa et al, 2003; 
Bagnasco et al, 2003). Moreover, ghrelin-induced food intake is ablated 
in GHSR knockout mice (Sun et al, 2004), indicating that feeding 
stimulatory effect of ghrelin is mediated via GHSR. Additionally, 
chronic ghrelin administration induces adiposity, supposedly by 
interaction with hypothalamic circuits controlling energy homeostasis 
(Tschöp et al, 2000). 
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Plasma ghrelin and ghrelin mRNA expression increase pre-prandially, 
i.e. anticipatory to meal initiation, and decrease post-prandially (Tschöp 
et al, 2000; Asakawa et al, 2001; Cummings et al, 2001; Toshinai et al, 
2001; Tschöp et al, 2001a; Ariyasu et al, 2002; Cummings et a, 2002b). 
Arvat and co workers (2000) discovered that a peripheral ghrelin 
injection increases hunger in healthy volunteers and subsequent studies 
have confirmed that ghrelin induces sensations of hunger and appetite 
(Horvath et al, 2001; Nakazato et al, 2001; Wren et al, 2001a; 
Eisenstein and Greenberg, 2003). Similarly, an intravenous 
administration of ghrelin to (healthy) humans increases the imagination 
of food (Schmid et al, 2005). Moreover, ghrelin increases behaviours 
such as sniffing and foraging for food (Keen-Rhinehart and Bartness, 
2004). Moreover, administration into the brainstem reduces the latency 
to begin eating and stimulates additional meals, but does not alter meal 
size in animals (Faulconbridge et al, 2003); thus indicating that ghrelin 
has a role in meal initiation. 
 
Ghrelin and deviant eating behaviours 
Several studies have demonstrated an association between anomalous 
plasma ghrelin levels and aberrant eating patterns (vide infra). It has 
been suggested that a hyperghrelinemia may have a role in the 
pathophysiology of binge eating (i.e. compulsive overeating), at least in 
bulimic, anorectic and Prader-Willi patients. Children with Prader-Willi 
syndrome, who have not yet developed the core symptoms, have 
normal plasma levels of ghrelin (Erdie-Lalena et al, 2006), whereas the 
ghrelin levels are increased along with development of hyperphagia 
and obesity (Cummings et al, 2002a; DelParigi et al, 2002; Haqq et al, 
2003; Erdie-Lalena et al, 2006). Similarly, anorectic and bulimic 
patients of the binge type have higher levels of ghrelin in the plasma 
than their non-binging counterparts, and the frequencies of bingeing 
correlate positively with plasma ghrelin levels (Tanaka et al, 2003a).  
 
Peripheral ghrelin levels are elevated in anorectic and bulimic subjects 
(Ariyasu et al, 2001; Otto et al, 2001; Shiiya et al, 2002; Tanaka et al, 
2002; Monteleone et al, 2003; Nedvidkova et al, 2003; Tanaka et al, 
2003b; Tolle et al, 2003; Soriano-Guillen et al, 2004; Stock et al, 2005) 
and decreased in obese, compared to lean, subjects (Tschöp et al, 
2001b; Wren et al, 2001b; Shiiya et al, 2002; Rosická et al, 2003; 
Soriano-Guillen et al, 2004; Stock et al, 2005). Moreover, obese 
individuals with BED have lower plasma levels of ghrelin than those 
without BED (Geliebter et al, 2004; Geliebter et al, 2005; Monteleone 
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et al, 2005). Additionally, following dietary inventions in obese and 
anorectic individuals the plasma ghrelin levels increase or decrease, 
respectively (Cummings et al, 2002b; Hansen et al, 2002; Soriano-
Guillen et al, 2004). However, it should be considered that the ghrelin 
levels in plasma may not correspond positively to the levels of ghrelin 
in brain areas such as the hypothalamus, VTA and LDTg.  
 
Various polymorphisms in the GHSR have been associated to bulimia 
nervosa, obesity (Wang et al, 2004b; Baessler et al, 2005; Holst and 
Schwartz, 2006; Miyasaka et al, 2006) and alterations in eating patterns 
(i.e. the proclivity to “gaze” versus “binge”) (Korbonits et al, 2004). 
Moreover, different pro-ghrelin gene polymorphisms have been linked 
to obesity, bulimia nervosa purging individuals (Ukkola et al, 2001; 
Korbonits et al, 2002; Vivenza et al, 2004; Ando et al, 2006; Vartiainen 
et al, 2006) as well as methamphetamine withdrawal (Yoon et al, 2005).  
 
Central nervous system targets 
The effects of ghrelin on energy balance have been shown to be 
mediated, at least in part, via the hypothalamus (Nakazato et al, 2001; 
Shuto et al, 2002). Specifically, the ghrelin-induced feeding is mediated 
via the hypothalamic arcuate nucleus (Tamura et al, 2002). NPY and 
agouti related peptide (AgRP) containing neurons in the arcuate 
nucleus have been demonstrated to mediate the orexigenic effects of 
ghrelin (Kamegai et al, 2001; Nakazato et al, 2001; Shintani et al, 2001; 
Wang et al, 2002; Olszewski et al, 2003; Toshinai et al, 2003; Chen et 
al, 2004; Riediger et al, 2004; Tang-Christensen et al, 2004; Gropp et al, 
2005). Further, an electrophysiology study has shown that ghrelin 
decreases the firing in proopiomelanocortin (POMC) neurons in the 
arcuate nucleus (Cowley et al, 2003). Moreover, it has been 
demonstrated that the ghrelin-induced feeding is mediated via central 
MC signalling (Tschöp et al, 2002; Chen et al, 2004) as well as orexin 
containing neurons (Toshinai et al, 2003). Taken together, the feeding-
stimulatory effects of ghrelin in the arcuate nucleus may possibly 
collectively be mediated via NPY/AgRP neurons and e.g. POMC, 
orexin and the MC systems.  
 
Aim of  the present thesis 
The overall aim of the present thesis was to investigate the 
mechanisms of action for ethanol and ghrelin on the DA reward 
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systems, and thereby pin point novel targets for treatment of addictive 
behaviours. 
Initially, the functional role the different nAChRs subunit 
compositions for the stimulatory and DA enhancing effects of ethanol 
was explored. In addition, the possibility that the orexigenic peptide 
ghrelin activate the reward systems, specifically the cholinergic-
dopaminergic reward link, was elucidated. In subsequent experiments 
the role of cholinergic mechanisms in mediation of the ghrelin-induced 
stimulation and DA overflow was studied.  
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Materials and methods 
To explore our hypotheses in the present thesis the following methods 
and experimental setups were used.  
 
Methods    Paper 
Peptide synthesis   I 
Locomotor activity recording  I, II, III, IV 
In vivo microdialysis    I, II, III, IV 
Radioligand binding assay  IV 
 
Peptide Synthesis 
The availability of ?-conotoxins is limited and in order to synthesis 
?CtxMII analogues with various nAChR subunit selectivity, a slightly 
modified method described my McIntosh and co-workers (Cartier et 
al, 1996) was used to synthesize ?-conotoxin peptides (i.e. ?CtxMII 
and the ?CtxPIA-analogue).   
 
Linear Peptides 
The peptides were synthesized on a Rink amide resin (loading 1.20 
mmol/g) using N-9-fluorenylmethoxycarboxyl (Fmoc) chemistry and 
O-(7-benzotriazole-1-yl)-1,1,3,3 tetramethyluronium tetrafluoroborate 
(TBTU) and N,N-diisopropylethyl amine (DIPEA) activation. The 
peptides were synthesized on a 0.24 mmol scale with standard amino 
acid side chain protection (Glu and Ser [t-Bu]; Asn and His [trityl] 
except on cysteine residues. Cysteine residues were protected in pairs 
with S-trityl on the first and third cysteines and S-acetamidomethyl on 
the second and fourth cysteines.  Each residue was used in a five-fold 
excess and coupled for 60 min. 
Following completion of the synthesis the resin was washed with 
methanol (3 x 10ml) and dried under reduced pressure.  
 
The linear peptide amide was cleaved of the resin by treatment with 6 
ml of trifluoroacetic acid/H2O/ethanedithiol /thioanisole (94.5/2.5/ 
2.5/1 by volume) for 6h at 20 °C. The resin was rinsed twice with 6 ml 
of the same solution. The combined filtrate and washings were pooled 
and concentrated to dryness. The residue was washed two times with 
diethyl ether. The supernatant was discarded and the precipitated 
peptide powder was dried on the vacuum line.  
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Peptide Cyclization 
To form a disulfide bridge between Cys and Cys (i.e. the first and third 
cysteines), the pelleted peptide was dissolved in 1.2 ml of B-Buffer 
(H2O/acetonitrile/trifluoroacetic acid (95/5/0.1 by volume)) and 
acetonitrile (40/60 by volume), with gentle swirling (to avoid foaming). 
The linear peptide solution was added drop-wise into 57 ml of H2O 
(pH 7.6 by solid Tris base). The solution was gently swirled at room 
temperature for 45 h when the reaction was judged to be complete by 
analytical HPLC using a Genesis C18 column (4μ, 15cm x 4.6mm; 
Jones Chromatography, Hengoed, USA) and a gradient from 5% to 
95% of B-Buffer in acetonitrile as eluent (flow rate at 1 ml/min). The 
pH of the solution was adjusted to 2-3 by the addition of 
trifluoroacetic acid and the solution was freeze-dried. The monocyclic 
peptide was then purified by preparative HPLC using an Ace 5AQ 
column (25cm x 21.2mm: Advanced Chromatography Technologies, 
Aberdeen, United Kingdom) and a gradient from 5% to 95% of B-
Buffer in acetonitrile as eluent (flow rate at 10 ml/min). The fractions 
containing product were pooled and freeze-dried.  
 
Removal of the S-acetamidomethyl groups and formation of the 
second disulfide bridge (Cys-Cys, i.e. the second and fourth cysteines) 
was carried out simultaneously by iodine oxidation. The monocyclic 
peptide was diluted in 3.5 ml of B-Buffer and added drop-wise to 3.5 
ml of a rapidly stirred solution of 20 mM iodine in H2O/trifluoroacetic 
acid/acetonitrile/MeOH (50/20/20/10 by volume) over 5.5 minutes 
at room temperature. This reaction was allowed to proceed for another 
90 minutes and was thereafter terminated by the addition of a diluted 
aqueous solution of ascorbic acid (1M, two drops). The solution was 
freeze-dried over night and the peptide was obtained as a powder.  The 
peptide was dissolved in 450 μl of B-Buffer and was purified by 
preparative HPLC as described above. The purity of the peptide was 
analyzed by analytical HPLC as described above. The peptide was 
thereafter freeze-dried and the amino acid sequence was analyzed by 
fast atom bombardment mass spectrometry (FAB-MS) (Einar Nilsson, 
Department of Organic Chemistry, Lund University, Sweden). The 
peptide was thereafter used in the animal experiment. 
  
Animals 
Adult male NMRI mice weighing approximately 25-40 g, purchased 
from either Charles River (Sulzfeld, Germany (paper I, II, III)) or 
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B&K Universal AB (Sollentuna, Sweden (Paper III, IV)) were used for 
the locomotor activity and microdilaysis experiments. Adult male 
Sprague Dawly rats weighing approximately 220 g, purchased from 
B&K were used for the radioligand binding experiments (Paper IV). 
Upon arrival the animals were allowed to habituate in groups of eight 
mice or six rats, in standard cages (Macrolon III: 400 x 250 x 150 mm 
(mice), Macrolon IV: 550 x 350 x 200 mm (rats)), for at least a week 
before initiation of the experiment. Standard feed (Harlan Teklad, 
Norfolk, England) and tap water were freely supplied from the arrival 
until the day of experiment. The cages and bedding material (wood-
cuttings) were changed once a week. A temperature of 20°C, humidity 
of 50% and a 12/12 hour light/dark cycle (light switched on 7 am) was 
maintained in the animal room. The present studies were approved by 
the Ethics Committee for Animal Experiments in Göteborg, Sweden. 
 
Locomotor activity procedure 
Most drugs of abuse cause locomotor stimulation, an effect, at least in 
part, mediated by their ability to enhance the extracellular 
concentration of accumbal DA (Engel and Carlsson, 1977; Wise and 
Bozarth, 1987) and may therefore be suggested to be a putative 
endophenotype for drugs of abuse (Gabby, 2005). Interestingly, low 
doses of ethanol stimulates the locomotor activity in alcohol-preferring 
but not in non-alcohol preferring rats (Waller et al, 1986) and the 
behavioural effects of ethanol in rats are closely time-locked with 
accumbal DA release (Imperato and Di Chiara, 1986). In addition, the 
locomotor and the positive reinforcing effects of addictive drugs has 
been suggested to be homologous effects evolving from an activation 
of a common mechanism in rodents and humans, i.e. the dopaminergic 
reward systems (Wise and Bozarth, 1987). Furthermore, locomotor 
activity is an important component of food-seeking behaviour and 
thus essential for survival.  
 
Device for measuring locomotor activity 
Locomotor activity was registered in eight sound attenuated, ventilated 
and dimly lit locomotor boxes (420 x 420 x 200 mm, Plexiglas®). Five 
by five rows of photocell beams at the floor level of the box allowed a 
computer-based system to register the activity of the mice 
(Kungsbacka mät- och reglerteknik AB, Fjärås, Sweden). The mice 
were allowed to habituate to the environment in the box for one hour 
before drug challenge and initialization of the experiment. This 
 49 
because naïve animals initially display a high exploratory activity which 
is followed by a decline in locomotor activity. To reduce the influence 
of injection-induced hyper-motility, the registration of locomotor 
activity started 5 minutes after the drug administration. Locomotor 
activity was defined as the accumulated number of new photocell 
beams interrupted during a 30-minute (Papers I, II) or 60-minute 
(Papers III, IV) period.  
 
Guide cannula implantation 
In papers I and IV, ?CtxMII and/or the ?CtxPIA-analogue were 
administered into the VTA, as these peptides may not pass the BBB. 
On the day of the locomotor experiment (Papers II, III and IV) the 
animals were challenged with a ghrelin injection into the third ventricle 
(from which drug distribution to other parts of the brain is known to 
occur) or injections into the VTA and/or the LDTg (for regional 
distribution). To facilitate this administration, bilateral and/or 
unilateral guide cannula/s, aiming at the VTA, the third ventricle or 
LDTg, was surgically implanted four days prior to the experiment 
using the method described below.  
The mice were anesthetized with isofluran (Isofluran Baxter: 
Univentor 400 Anaesthesia Unit, Univentor Ldt., Zejtun, Malta), 
placed in a stereotaxic frame (David Kopf Instruments: Tujunga, CA, 
USA) and kept on a heating pad to prevent hypothermia. The skull 
bone was exposed and one or two holes for the guide cannulas 
(stainless steel, length 10 mm, outer/inner diameter of 0.6/0.45 mm) 
and one for an anchoring screw were drilled. Following surgery, 1 ml 
of saline was injected subcutaneously (sc) to avoid dehydration. 
The coordinates for the VTA relative to the bregma were: posterior –
3.4 mm, lateral to midline ±0.5 mm, for the third ventricle: posterior -
0.9 mm, lateral to midline ±0.0 mm, and for the LDTg: 5.0 mm 
posterior to bregma, ±0.5 mm lateral to the midline (Franklin and 
Paxinos, 1996). The guide cannula/s were lowered 1.0 mm below the 
surface of the brain and was fixed to an anchoring screw and the scull 
with dental cement (DENTALON? plus: AgnTho’s AB, Lidingö, 
Sweden). After surgery the mice were kept in individual cages 
(Macrolon III (Paper I), Sealsafe IVC 2L, 365 x 207 x 140 mm (Papers 
II, III, IV)), with food and water supplied ad libitum and allowed to 
recover for four days before the locomotor activity test.  
At time of the experiment the infusion cannula was inserted and 
extended another 3.8 mm, 1.1 mm, 2.2 mm ventrally beyond the base 
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of the guide cannula, aiming at the VTA, third ventricle and LDTg 
respectively. 
 
Locomotor experiment procedure 
On the day of the experiment the guide cannula was used to administer 
drug into the VTA, third ventricle or LDTg. Before initiating the 
experiment, a dummy cannula was carefully inserted into the guide 
cannula and then retracted to remove clotted blood and to hamper 
spreading depression. Spreading depression occurs as a result of 
injuries to brain tissues, causing release of ions and other compounds, 
and thereby interfering with the animal’s normal function. Previous 
studies from the present laboratory indicate that the probability of a 
second spreading depression is largely reduced by pre-insertion of a 
dummy cannula.  
 
Paper I: Either ?CtxMII (5 nmol in 1μl), the ?CtxPIA-analogue (5, 10, 
20 nmol in 1μl) or an equal volume of vehicle (Ringer solution) was 
carefully administered bilaterally into the VTA to one side at the time. 
Twenty minutes later ethanol (1.75 g/kg) or vehicle (saline) was 
administered intraperitoneally (ip).  
 
Paper II: In the first locomotor activity experiment, ghrelin (1 μg in 1 
μl) or an equal volume of vehicle (Ringer solution) was administered 
into the third ventricle. In the second locomotor activity experiment 
the mice were first challenged with MEC (2.0 mg/kg) or vehicle 
(saline) ip. Ten minutes later ghrelin (1 μg in 1 μl) or an equal volume 
of vehicle (Ringer solution) solution was administered into in the third 
ventricle. 
 
Paper III: In these experiments ghrelin (1 μg in 1 μl) or an equal 
volume of vehicle solution (Ringer solution) was administered 
bilaterally either into the VTA or the LDTg.  
 
Paper IV: In the first series of experiments, mice were unilaterally pre-
treated with MEC (5 pmol in 1 μl), ?CtxMII (50 pmol in 1 μl) or an 
equal volume of vehicle (Ringer solution) into the VTA and 10 or 20 
minutes later ghrelin (2 μg in 1 μl) or an equal volume of vehicle 
(Ringer solution) were injected into the LDTg. In the second series of 
experiments, mice were pre-treated with DH?E (0.5 mg/kg, sc), MLA 
(2 mg/kg, ip) or vehicle (saline) and 10 minutes later ghrelin (1 μg/ in 
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μl) or an equal volume of vehicle (Ringer solution) were injected 
bilaterally into the LDTg. In the third series of experiments, mice were 
bilaterally pre-treated with MEC (5 pmol in 1 μl), ?CtxMII (50 pmol 
in 1 μl) or an equal volume of vehicle (Ringer solution) into the VTA 
and either ghrelin (1 μg in 1 μl) or an equal volume of vehicle (Ringer 
solution) into the VTA. In the fourth series of experiments, mice were 
pre-treated with DH?E (0.5 mg/kg, sc), MLA (2 mg/kg, ip) vehicle 
(saline) and 10 minutes later ghrelin (1 μg in 1 μl) or an equal volume 
of vehicle (Ringer solution) were injected bilaterally into the VTA. 
 
In all the locomotor activity experiments the mice were returned to the 
locomotor activity boxes after each drug administration. All mice 
received drug treatment only once. In all experiments with local drug 
administrations the drug was administered for one minute, the cannula 
was left in place for another minute, and was then retracted. A 
cannnula connected to a 5 μl syringe (Kloehn microsyringe: 
Skandinaviska Genetec AB, V. Frölunda, Sweden) was used for the 
local drug administrations. Neither water nor food was available to the 
animal during the locomotor experiments.  
 
Statistical analyses for locomotor activity 
All data obtained from the experiments were statistically analyzed 
using SAS Statview 5.01 computer software (Eudorex Sales AB, 
Stockholm, Sweden). A probability value (p) less than 0.05 was 
considered as statistically significant. Error bars in the figures represent 
standard error of the mean (S.E.M).  
 
The data were evaluated by one- or two-way analysis of variance 
(ANOVA) followed by Fisher’s protected least significant difference 
test (PLSD) for comparisons between treatments (Papers I, II, IV). In 
Paper III the Bonferroni procedure was used for post-hoc 
comparisons between different treatments. Unpaired t-test was also 
used to analyse the locomotor activity data. 
 
Microdialysis procedure 
Ungerstedt (Ungerstedt, 1983) and Johnson and Justice (Johnson and 
Justice 1983) introduced in vivo microdialysis in awake and freely 
moving animals, and the technique is now well established and 
commonly used. Previous work from the present laboratory has 
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adapted the in vivo microdialysis method from rats to mice. The 
microdialysis technique enables measurements of extracellular 
neurotransmitter levels in the brain in awake, freely moving mice. The 
method is based on the movement of substances from the outside the 
probe to the inside. High extracellular DA concentrations may depend 
on rapid saturation of the DA transporter, slow enzymatic degradation, 
DA released from other cells, diffusion from other areas, slow 
autoreceptor activation and/or burst firing. The method cannot 
distinguish between these different origins of DA. In the present 
experiments the technique was used to monitor the drug-induced 
changes in extracellular levels of dopamine in N.Acc.. Dialysates were 
sampled at 20 minutes intervals, and thus, an obvious limitation was 
that real-time estimations of alterations in transmitter levels could not 
be estimated. It should therefore be noted that the technique does not 
reflect synaptic release, but an averaged “overflow” of the extracellular 
DA that escapes reuptake and breakdown mechanisms.      
 
Probe manufacturing 
All probes were manufactured on site, where a modified version of the 
microdialysis probes described by Santiago and Westerink (Santiago 
and Westerink, 1990) was used. The probe production was facilitated 
by specific stands (Medi Tech, Göteborg University, Sweden). The 
inlet and the outlet of the probe were made of PE20 polyethylene 
tubing (outer/inner diameter of 1.09/0.38 mm: Becton Dickinson and 
Company, Sparks, MD, USA). A fused silica extended 5 mm from the 
tip of the probe. A glass rod was centred between the inlet and outlet 
and was attached by Super Epoxy (Loctite, Göteborg, Sweden). The 
dialysis membrane (20 000 kDa cut off with an outer/inner diameter 
of 310/220 μm: HOSPAL, Gambro, Lund, Sweden), prepared from a 
co-polymer of polyacrylonitrile and sodium methallyl sulfonate, was 
sealed with a glue plug and thereafter tread on the fused silica. The 
exposed tip of the dialysis membrane of the probe was 1 mm; the 
remaining membrane area was covered with silicone glue (CAF 3: 
Rhodorsil Silicones, Saint-Fons Cedex, France). Each probe was 
controlled to ensure that is was straight and that the flow was correct. 
The probes were thereafter connected to a microperfusion pump (U-
864 Syringe Pump: AgnThós AB) and firstly perfused with an ethanol 
solution (70% vol./vol.; 100 μl) and secondly with an artificial 
cerebrospinal fluid (Ringer solution; 200μl) at a rate of 4 μl/min. The 
 53 
probes were sealed by heating and stored in Ringer solution for 
maximum 1 day in 6°C before implantation. 
   
Surgical procedure 
The mice were implanted with a microdialysis probe (Waters et al, 
1993) positioned in the N.Acc. for measurement of extracellular DA 
levels, and a guide cannula, aiming at the VTA, the third ventricle 
and/or the LDTg (to enable drug administration). The location of the 
probe and guid cannula was ipsilateral and alternated to both the left 
and right side of the brain. The surgical procedure was performed as 
described above (see Guide cannula implantation), where the probe was 
slowly lowered into position and anchored to the screw in the skull 
bone with dental cement (Dentalon Plus; Angthós AB). Thereafter the 
guide cannulas were lowered into position and anchored to the probe 
with dental cement (Dentalon Plus: Angthós AB).  
The coordinates for the N.Acc. were: relative to the bregma +1.5 mm 
anterior, lateral to midline ±0.8 and ventral –4.7 mm. The coordinates 
for the VTA, third ventricle and the LDTg were the same as above 
(see Guide cannula implantation) (Franklin and Paxinos, 1996). At time of 
the experiment the cannula was inserted and extended another 3.8 
mm, 1.1 mm, 2.2 mm ventrally beyond the base of the guide cannula, 
aiming at the VTA, third ventricle and LDTg respectively. 
 
After surgery the mice were housed in individual cages (Macrolon III 
(Paper I), Sealsafe IVC 2L, 365 x 207 x 140 mm (Paper II, III, IV) with 
the food and water supplies ad libitum. The animals were allowed to 
recover for four days before the microdialysis experiment. To ensure a 
good health status of the mice, the weight of the mice was registered 
prior to the experiment and after.  
 
Microdialysis drug treatment paradigm 
On the day of the experiment and immediately before start of the 
experiment, a dummy cannula was carefully inserted into the guide 
cannula and thereafter retracted to remove clotted blood and to 
hamper spreading depression (see Locomotor experiment procedure). The 
probe was then connected to a microperfusion pump (U-864 Syringe 
Pump: AgnThós AB) and perfused with vehicle (Ringer solution) at a 
rate of 1.5 μl/min. The mice were connected to the microdialysis 
apparatus via a liquid swivel (CMA/Miceodialysi AB, Stockholm, 
Sweden) and were able to move freely during the experiment. After 
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one hour of habituation to the microdialysis perfusion set up, 
perfusion samples (30 μl) were collected every 20 minutes. Five 
samples were collected prior to the first drug challenge. The baseline 
DA level was defined as the averaged concentration of the three 
consecutive samples before the first drug challenge. 
 
Paper I. Ethanol (1.75 g/kg, ip) was administered at time 0 minutes. 
Three hours later the ?CtxPIA-analogue (5 nmol in 1μl) or an equal 
volume of vehicle (Ringer solution) was administered into the VTA. 
Twenty minutes after the local drug administration an additional 
ethanol (1.75 g/kg, ip) or vehicle (saline, ip) injection followed, and 
another four samples were collected.  
 
Paper II. In the first microdialysis experiment ghrelin (1 μg in 1 μl) or 
an equal volume of vehicle (Ringer solution) was administered into the 
third ventricle at 10 minutes. In the second microdialysis experimental 
setup the unselective nicotinic antagonist MEC (2 mg/kg, ip) or 
vehicle (saline, ip) was administered at 0 minutes and 10 minutes later 
ghrelin (1 μg in 1 μl) or an equal volume of vehicle (Ringer solution) 
were administered into the third ventricle.  
 
Paper III. In this microdialysis experimental setup, at 10 minutes, 
ghrelin (1 μg in 1 μl) or an equal volume of vehicle (Ringer solution) 
were administered into the VTA or LDTg.  
 
Paper IV. In this microdialysis experimental setup, ?CtxMII (50 pmol 
in 1 μl) or an equal volume of vehicle (Ringer solution) were 
administered into the VTA. 20 minutes later, ghrelin (1 μg in 1 μl) or 
an equal volume of vehicle (Ringer solution) was administered into the 
VTA or LDTg. Mice only received a ghrelin injection into VTA or 
LDTg 
 
In papers II, III and IV, perfusion samples were collected for three 
hours (9 samples) after the last drug injection. At the end of the 
experiment amphetamine (2 mg/kg, ip) was administered; mice 
without amphetamine-induced DA overflow in the N.Acc. were 
excluded from the statistical analysis. The experiments was then 
terminated. In all microdialysis experiment the mice were returned to 
microdialysis cage after each drug administration. All mice received 
drug treatment only once. In all experiments with local drug 
administrations the drug was administered for one minute, the cannula 
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was left in place for another minute, and was then retracted. Neither 
water nor food was available to the animals during the microdialysis 
experiments.  
 
Biochemical assay 
The DA levels in the dialysates were determined by means of HPLC 
with electrochemical detection (HPLC-EC). A pump (Gyncotec 
P580A: Kovalent AB, V. Frölunda, Sweden), an ion exchange column 
(2.0 x 100 mm, Prodigy 3 μm SA, Skandinaviska GeneTec AB) and a 
detector (Antec Decade: Antec Leyden, Zoeterwoude, The 
Netherlands) equipped with a VT-03 flow cell (Antec Leyden) was 
used. The mobile phase (pH 5.6), consisting of sulfonic acid (10 mM), 
citric acid (200 mM) sodium citrate (200 mM), 10% EDTA, 30% 
MeOH, was vacuum filtered by using a 0.2 μm membrane filter (GH 
Polypro: PALL Gelman Laboratory, Lund, Sweden). The mobile phase 
was delivered at a flow rate of 0.2 ml/min passing a degasser (Degas 
Populaire: Kovalent AB), and the analyte was oxidized at +0.4 V. The 
analysis was kept under constant temperature (+ 25°C). 
 
An external DA standard with a concentration of 3.26 nM was used to 
identify the DA peak. The limit of detection at a signal/noise ratio 3:1 
was 4 fmol DA/20 μl injection. Basal, average baseline levels of the 
extracellular the DA concentration were approximately 1 nM. 
 
Statistical analyses of the microdialysis experiments 
All data obtained from the experiments were statistically analyzed 
using SAS Statview 5.01 computer software (Eudorex Sales AB). A 
probability value (p) less than 0.05 was considered as statistically 
significant. Error bars in the figures represent S.E.M. The baseline DA 
level was defined as the averaged concentration of the three 
consecutive samples before the first drug challenge (time point 0 min). 
 
Paper I: The microdialysis data were analyzed by paired or unpaired t-
tests. The baseline DA concentration preceding the first ethanol-
induced increase in DA overflow was defined as the averaged 
concentration of the two consecutive samples obtained before ethanol 
challenge (time point 0 min) and the peak increase as the averaged 
concentration of the two consecutive samples obtained at 80 and 100 
min. The baseline DA concentration preceding the second ethanol-
induced increase in DA overflow was defined as the averaged 
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concentration of the two consecutive samples obtained at 160 and 180 
min and the peak increase as the averaged concentration of the two 
consecutive samples obtained at 220 and 240 min. Paired t-tests were 
used to investigate the maximum DA increase for the respective peaks 
in each treatment group. Differences between treatment groups in 
ethanol-induced DA overflow were analyzed by unpaired t-tests.  
 
Paper II: The microdialysis data were analyzed with a two-way 
ANOVA, with treatment as between-subjects factor and time as 
within-subjects factor, followed by Fisher’s PLSD test for comparison 
between treatments. Changes from baseline between treatment groups 
in ghrelin-induced DA overflow at every time point were analyzed by 
unpaired t-tests. A paired t-test was used to analyze the effect of 
ghrelin compared to its own baseline.  
 
Paper III: Two-way ANOVA was performed on the data obtained 
with treatment as between-subjects factor and time as within-subjects 
factor. The Bonferroni procedure was used for post-hoc comparisons 
between different treatments.  
 
Paper IV: The microdialysis data were analyzed with a two-way 
ANOVA, with treatment as between-subjects factor and time as 
within-subjects factor, followed by Fisher’s PLSD test for comparison 
between treatments. Changes from baseline within the representative 
treatment groups in ghrelin-induced DA overflow at the different time 
points were analyzed by Fisher’s PLSD, following a significant two-
way ANOVA. 
 
Verification of probe and/or guide cannula/s 
placement 
After the locomotor activities as well as the microdialysis experiments 
were completed, the locations of the probe and/or cannula/s were 
verified. The mice were decapitated, probes were perfused with 
pontamine sky blue 6BX to facilitate probe localization, and the brains 
were mounted on a vibroslice device (752M Vibroslice: Campden 
Instruments Ltd., Loughborough, UK). The brains were cut in 50 μm 
sections and the location of the probe and/or cannula was determined 
by gross observation using light microscopy. Only mice with guide 
cannula/s placement in the third ventricle (Fig. 9A), VTA (Fig. 9B), 
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LDTg (Fig. 9C) and/or probe placement in the N.Acc. (Fig. 9D) were 
included in the statistical analysis. 
 
Fig. 9. Coronal mouse brain sections showing guide cannula/s and/or probe 
placement. 
A. Cannula placements within the third ventricle of ten representative mice. 
B. Cannula placements within the ventral tegmental area of six representative mice. 
C. Cannula placements within the laterodorsal tegmental area of six representative 
mice.  
D. Probe placements within the nucleus accumbens of ten representative mice. All 
brain sections are reprinted from The Mouse Brain in Stereotaxic Coordinates, K. B. J. 
Franklin and G. Paxinos, figure 17, 18, 19. Copyright (1996), with permission from 
Elsevier. 
 
Radioligand binding assay 
Tissue preparation 
The rats (n=26) were decapitated, the brains rapidly removed and 
dissected on ice. Bilateral VTAs, from each rat, were saved and stored 
at -70 °C until use. On the day for the binding experiment, the brain 
tissue was homogenized in 50 mM TRIS pH 7.7 (approximately 0,2 g 
tissue in 20 ml TRIS) with a glass/Teflon homogeniser. The 
homogenized tissue was centrifuged (Beckman, Model J2-21 
centrifuge) at 16,000 g for 25 min and +4 °C. The pellet was recovered 
A. B.
C. D.
Bregma -5.0 mm
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and dissolved in 20 ml distilled water. 60 minutes later the solution was 
centrifuged (Beckman, Model J2-21 centrifuge) at 16,000 g for 25 min 
and +4 °C. The pellet was recovered and dissolved in 20 ml 50 mM 
TRIS pH 7.7 and was centrifuged again at 16,000 g for 25 min and +4 
°C. Finally the pellet was recovered and re-suspended in 8.6 ml 50 mM 
TRIS pH 7.7. 
 
Binding assay 
The total vial volume for the binding assay was 500 μl: 300 μl of tissue 
suspension, 100 μl of 5 nM [3H]-nicotine, 50 μl of volume adjustment 
and 50 μl of the different competing drugs used (nicotine or ghrelin) at 
increasing concentrations (0-200 μM) dissolved in 50 mM TRIS pH 
7.7. For each drug, eight different concentrations were used. The 
samples were incubated for 90 minutes at +4 °C and thereafter filtered 
with a cell harvester (Brandel, Biomedical Research and 
Developmental Laboratories, Gaitherburg, USA). Glass microfibre 
filter (GF/B; Whatman, Maidstone, England) and ice-cold 50 mM 
TRIS pH 7.7 were used. The filters were rinsed twice with 4.5 ml 50 
mM TRIS pH 7.7, thereafter 5 ml scintillation liquid (Optiphase “Hi 
Safe” 2; NEN Life Science, Sollentuna, Sweden) was added and the 
samples were incubated shaking over night. Thereafter the samples 
were counted in a multi-purpose scintillation counter (Beckman LS 
6500, Beckman Instruments). All determinations were performed in 
duplicates. 
 
Drugs 
?CtxMII and the ?CtxPIA-analogue were dissolved in Ringer solution 
(NaCl 140 mM; CaCl2 1.2 mM; KCl 3.0 mM and MgCl2 1.0 mM) 
(Merck KGaA, Darmstadt, Germany). 
 
Paper I: The dose of ?CtxMII (5 nmol in 1 μl) used, was selected on 
the bases of pervious dose-finding experiments to select the highest 
dose that did not affect locomotor activity per se (data not shown).  In a 
similar manner 5 nmol in 1 μl for the ?CtxPIA-analogue was used.  
 
Paper IV: The dose of ?CtxMII (50 pmol in 1 μl) used, was selected 
on the bases of previous experiments showing that the operant leaver 
response for ethanol and the alcohol deprivation effect could be 
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antagonized by a lower dose of ?CtxMII (Kuzmin, Jerlhag, Liljequist, 
Engel, unpublished data).  
 
Ethanol (VWR International AB, Stockholm, Sweden) was diluted in a 
0.9% sodium chloride solution to a 15% (weight/volume) 
concentration and was administrated ip. MEC hydrochloride (Sigma-
Aldrich Sweden AB, Stockholm, Sweden) was dissolved in sodium 
chloride solution (0.9 %) (Paper II) or Ringer solution (Paper IV) and 
administered ip (2 mg/kg, 10 ml/kg body weight) (Paper II) or into 
the VTA (5 pmol in 1 μl) (Paper IV). Saline vehicle contained 0.9% 
sodium chloride solution and was administered 12 ml/kg. The dose 
used for MEC was base on previous dos-response experiments in our 
research group and found to be the highest dose with no effect per se 
on locomotor activity (data not published). Active (acylated) rat ghrelin 
(Bionuclear, Bromma, Sweden) was dissolved in Ringer solution. The 
selected dose of ghrelin was used since this dose has been reported to 
statistically significantly increase the food intake in mice (Bjursell et al, 
2005). Methyllycaconitine HCl or dihydro-?-erythroidine HBr (Sigma-
Aldrich Sweden AB) were dissolved in sodium chloride solution (0.9 
%) and were administered ip or sc, respectively. The selected doses 
were used since they have been shown to antagonize the locomotor 
stimulatory and DA enhancing effects of nicotine (Larsson et al, 2002). 
Dex-amphetamine sulphase (RBI, Natick, USA) was dissolved in 
sodium chloride solution (0.9 %) and administered ip (2 mg/kg, 10 
ml/kg body weight). The drug challenges were randomized in all 
experiments. All drugs were administered as the weight of the salt.  
[3H]-nicotine (NEN Life Science Products), nicotine (Sigma-Aldrich 
Sweden AB), TRIS (Trisma pre-set crystals; Sigma-Aldrich Sweden 
AB) and scintillation liquid (Optiphase “Hi Safe” 2; NEN Life Science 
Products) were used for the radio-ligand binding experiments.  
 
Methodological considerations 
Ghrelin and ethanol increases the locomotor activity and accumbal DA 
(Papers I, II, III, IV), indicating that both these drugs have rewarding 
properties. However, it should be emphasized that these measures do 
not directly reflect reward but are rather mechanisms associated with 
reward. Given that in vivo microdialysis enables measurements of the 
extracellular concentration of DA and that the N.Acc. core and shell 
are closely associated (especially in a small animal like the mouse), it 
may be suggested that in the present experiments we measure DA 
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levels in both these areas. However, this appears less likely since dorsal 
and/or lateral placement of the probe does not demonstrate an 
increase in accumbal DA upon ethanol or ghrelin administration. Most 
drugs of abuse cause locomotor stimulation (Engel and Carlsson, 
1977), an effect mediated by the ability of these drugs to enhance 
accumbal DA overflow. Locomotor activity is therefore a putative 
endophenotype for drugs of abuse. In addition, the locomotor and the 
positive reinforcing effects of addictive drugs has been suggested to be 
homologous derived from an activation of a common mechanism, i.e. 
the dopaminergic reward systems (Wise and Bozarth, 1987). The 
duration of the locomotor stimulation was shorter than that for 
accumbal DA overflow (Papers I, II, III, IV). This may be due to the 
fact that the in vivo microdialysis method measures the extracellular DA 
levels, which does not reflect synaptic release, but rather an averaged 
“overflow” of the extracellular DA concentration. This may be 
elucidated by methods such as in vivo electrochemistry or non-net flux. 
Additionally, an obvious limitation to the experimental techniques used 
in the present thesis is that real-time measurements of alterations in 
transmitter levels are not possible. However, in vitro 
electrophysiological studies on slices from the VTA show that ghrelin 
increases the firing rate of dopaminergic neurons in the VTA and 
systemic administration of ghrelin increases the in vitro turnover of DA 
in the N.Acc. (Abizaid et al, 2006a) Taken together, we suggest that 
ghrelin activates the mesolimbic DA system and therefore is a part of 
the neruochemical overlap between the reward systems and those 
regulating energy balance. 
It should be emphasized that the mouse brain may not represent the 
human brain. However, we believe that our animal models have 
validity. 
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Results and discussion 
?-Conotoxin MII and the ?-conotoxin PIA-
analogue can be efficiently synthesized (Paper 
I) 
The method used in Paper I was slightly modified from a method by 
McIntosh and co-worker (Cartier et al, 1996). These were 
modifications in reaction times, volumes as well as different 
purification columns. Results from analytical HPLC and FAB-MS 
analysis confirmed the purity and the identity, respectively, of the 
synthesized ?CtxMII and our ?CtxPIA-analogue. Furthermore, co-
injection of our in house-synthesized and in purchased ?CtxMII 
showed an identical eluation profile and both peptides attenuated the 
ethanol-induced locomotor stimulation (Larsson et al, 2004; Paper I). 
Taken together, this indicates that we efficiently could synthesize the 
?CtxMII and its peptide analogues.  
 
The ?CtxPIA has been reported to have higher selectivity for the ?6* 
than for the ?3?2* and/or ?3* subunits (Dowell et al, 2003). In the 
present series of experiments an analogue to ?CtxPIA was synthesized 
in which the N-terminal arginine had been removed whereas the 
remaining part including the central amino acids and the C-terminal of 
the peptide was left intact. It cannot be excluded that the synthesized 
?CtxPIA-analogue is different from the native ?CtxPIA in subunit 
selectivity. However, this appears less likely since the nAChR subunit 
selectivity of 4/7 ?-conotoxins has been reported to involve the amino 
acid residues in the central and the C-terminal part of the peptide, 
whereas the N-terminal appears to be of less importance (McIntosh et 
al, 1999; Arias and Blanton, 2000; Dutertre and Lewis, 2004; Everhart 
et al, 2004; Dutertre et al, 2005). Specifically, the bulky charged N-
terminal protrusion of ?CtxPIA has been suggested to be of less 
importance for its interaction with the ?6* subunit (Chi et al, 2005).   
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?-Conotoxin MII-sensitive receptors are 
involved in mediating the ethanol-induced 
locomotor stimulation (Paper I) 
In Paper I it was showed that bilateral administration of our 
synthesized ?CtxMII into the VTA significantly antagonized the 
ethanol-induced locomotor stimulation. This is in agreement with our 
previous experiments with purchased ?CtxMII (Larsson et al, 2004). It 
is important to emphasize that only the acute effects of ethanol was 
investigated in the paper and this does not represent the 
neurochemical alterations observed in alcohol dependent patients. 
However, we have previously shown that VTA administration of 
?CtxMII reduces ethanol intake and preference in high alcohol-
preferring mice and rats (Larsson et al, 2004). The dose (5 nmol) used 
in the present experiments may be high, and therefore unselective, 
raising the possibility that other subunits than the ?3?2*, ?3* and/or 
?6* may be involved in mediating the behavioural and neurochemical 
effects of ethanol. In preliminary experiments we have found that 
administration of our synthesized ?CtxMII into the VTA in a lower 
dose than previously used (2.5 pmol) also antagonizes ethanol-induced 
locomotor stimulation in mice (Fig. 10, unpublished data).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10. A low dose of ?-conotoxin MII (2.5 pmol in 1 μl), bilaterally 
administered into the ventral tegmental area antagonizes the ethanol-induced 
(EtOH, 1.75 g/kg, ip) locomotor stimulation in mice. 
Shown are the mean values ± S.E.M. of 6 observations in each group. *p<0.05, 
Fisher’s PLSD, following significant ANOVA. 
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A role of these subtypes in ethanol-induced reward is further 
supported by results demonstrating that infusion of a low dose of 
?CtxMII into the VTA (1) diminishes the conditioned reinforcing 
properties of alcohol cues (Löf, 2006) and (2) blocks the operant lever 
pressing for alcohol and the excessive alcohol consumption following 
a period of alcohol deprivation (Kuzmin, Jerlhag, Liljequist, Engel, 
unpublished data). In summary, this implies that ?CtxMII-sensitive 
nAChRs, ?3?2*, ?3* and/or ?6* subtypes, are involved in mediating 
several different aspects of ethanol addiction. 
 
?-Conotoxin PIA-analogue-sensitive receptors 
are neither involved in mediating the ethanol-
induced locomotor stimulation nor accumbal 
dopamine overflow (Paper I) 
Given that the different subunits can be expressed in various 
combinations in either heteromeric or homomeric receptors with 
different distribution patterns and functional roles (for review see 
Nicke et al, 2004), it is possible that particular subunit combinations of 
the nAChR may be involved in mediating the stimulatory and DA 
enhancing effects of ethanol. Interestingly, it has previously been 
demonstrated that the ?3?2*, ?3* and/or ?6* (using ?CtxMII) rather 
than the ?4?2* or ?7* (using DH?E or MLA respectively) nAChRs are 
involved in mediating the stimulatory, rewarding and DA enhancing 
effects of ethanol (Larsson et al, 2002; Larsson et al, 2004). In Paper I 
we provided additional information on the functional role of the ?6* 
subtype. It was found that bilateral administration of our synthesized 
?CtxPIA-analogue (selective for the ?6* subtype) into the VTA 
neither antagonized the ethanol-induced locomotor stimulation nor the 
increase of DA in the N.Acc. (Fig. 11). Tus indicating that the 
stimulatory and DA enhancing effects of ethanol might be mediated 
via ?CtxMII- rather than ?CtxPIA-analogue-sensitive nAChRs in the 
VTA, i.e. ?3?2*, ?3* nAChRs. 
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Fig. 11. Our in house-synthesized ?-conotoxin PIA-analogue (5 nmol), 
unilaterally administered into the ventral tegmental area, does not antagonize 
the ethanol-induced (EtOH, 1.75 g/kg, ip) dopamine overflow in nucleus 
accumbens in mice measured by in  v i vo  microdialysis.  
Ethanol was administered the first time at 0 minutes, vehicle or ?-conotoxin PIA-
analogue was administered at 180 minutes. After 20 minutes, from the beginning of 
drug administration followed the second ethanol (EtOH, 1.75 g/kg, ip). Shown are 
mean values ± S.E.M. 
 
In line with this hypothesis, the expression of the ?3 subunit by ventral 
tegmental DA neurons has been reported (Klink et al, 2001). 
Additionally, 18-methoxycoronaridine, selective for the ?3?4* nAChR, 
reduces ethanol intake in rats (Rezvani et al, 1997; Maisonneuve and 
Glick, 2003). Furthermore, MEC has been reported to have affinity for 
the ?3?4* and ?3?2* at least when expressed in Xenopus oocytes (Papke 
et al, 2001) and MEC antagonizes the stimulatory, rewarding and DA 
enhancing effects of ethanol (e.g. Blomqvist et al, 1997; Ericsson et al, 
1998; Larsson et al, 2002). MLA may, in addition to the ?7, interact 
with the ?6 subunit (Vailati et al, 1999). When it is taken to account 
that MLA does neither antagonize ethanol-induced locomotor 
stimulation nor accumbal DA overflow (Larsson et al, 2002), it may be 
implied that the ?3* subtype, rather than the ?6* containing nAChRs, 
is involved in mediation of these effects of ethanol.  
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Considering that voluntary ethanol concomitantly increases ventral 
tegmental ACh and accumbal DA levels (Larsson et al, 2005) and that 
nAChRs in the VTA mediate the stimulatory, rewarding and DA 
enhancing effects of ethanol (Blomqvist et al, 1997; Ericsson et al, 
1998; Larsson et al, 2002; Larsson et al, 2004), it is likely that ethanol 
activates the cholinergic (LDTg/PPTg)-dopaminergic (VTA) reward 
link. Natural rewards such as food has been shown to activate this link 
(Lanca et al, 2000; Rada et al, 2000; for review see Wise, 2002) and this 
prompted us to investigate the effects of the orexigenic peptide ghrelin 
on this system. 
 
The orexigenic peptide ghrelin increases 
locomotor simulation and accumbal dopamine 
overflow in mice (Paper II and III) 
Here we provide the first indication that the orexigenic peptide ghrelin 
activates the mesolimbic DA system, since administration of ghrelin 
into the third ventricle increases locomotor activity (Fig. 12A) and 
accumbal concentrations of DA (Fig. 12B). 
A.                                                        B. 
Fig. 12. Ghrelin (1μg in 1 μl), administered into the third ventricle, increases the 
locomotor activity (A) and accumbal dopamine overflow (B) in mice. 
A. Data are presented as the accumulated counts during the entire 30 minute-period. 
Shown are the mean values ± S.E.M. of 7-8 observations in each group.  
B. Ghrelin was administered at 10 minutes. Shown are mean values ± S.E.M. of 4-5 
observations in each group. Filled squares represent ghrelin and unfilled circles 
represent vehicle treatment.  
* p<0.05 Fisher PLSD, following significant ANOVA. 
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This suggests that ghrelin activates the DA reward systems and may 
constitute a part of the neurochemical overlap between the reward 
systems and the systems regulating energy balance. Experiments on 
hypothalamic synaptosomes have, however demonstrated that ghrelin 
do not modify the release of DA or NA but rather inhibits the 5-HT 
release (Brunetti et al, 2002). Even though this experimental design 
differs significantly from our it may be suggested that ghrelin has DA 
enhancing properties in the N.Acc. but not in the hypothalamus. In 
line with our hypothesis, systemic administration of ghrelin increases 
the ex vivo DA turnover in N.Acc. (Abizaid et al, 2006a). Additionally, 
icv administration of ghrelin markedly increased spontaneous 
locomotor activity in rats, an effect blocked by pre-treatment with the 
DA antagonist haloperidol (Jászberényi et al, 2006). Contrarily, 
locomotor activity has been reported to decrease upon icv ghrelin 
infusion (Tang-Christensen et al, 2004). This apparent inconsistency 
could be explained by differences in the availability of food.  In Paper 
II, increased locomotor activity was observed following an acute icv 
ghrelin injection to mice without food present during the experiments, 
possibly leading to food-seeking (locomotor activation) behaviour.  By 
contrast, ad libitum access to food during the study of Tang-
Christiansen et al would be expected to lead to satiety and hence, less 
food-seeking and locomotor activity.  
 
In rat and humans the GHS-R1As are expressed in the VTA as well as 
the LDTg  (important reward nodes) (Guan et al, 1997) raising the 
possibility that the stimulatory and DA enhancing effects of ghrelin 
may involve activation of one or of both these sites. In fact, we have 
found that administration of ghrelin into the LDTg (Fig. 13A) or the 
VTA (Fig. 13B) increases locomotor activity and accumbal DA 
overflow in mice (Paper III).  
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Fig. 13. Ghrelin (1 μg in 1 μl), administered into (A) the laterodorsal tegmental 
area or (B) ventral tegmental area, increases the extracellular concentration of 
dopamine in nucleus accumbens in mice measured by in v i vo  microdialysis.  
Ghrelin was administered at 10 minutes. Shown are mean values ± S.E.M. p < 0.001, * 
p<0.05, ** p<0.01, *** p<0.01, Bonferroni post-hoc test, following a significant 
ANOVA. 
 
It should be emphasized that ghrelin, in Paper III (and IV), was locally 
injected into the VTA and/or LDTg at a volume of 1μl, raising the 
concern that some solution might spread throughout the brain and 
thereby reach and activate other important areas such as the closely 
located PPTg. A role for PPTg in the rewarding and motivational 
properties of addictive drugs as well as in the rewarding properties of 
natural rewards has been found (for references see Cholinergic regulation 
of the ventral tegmental area). Additionally, in C57Bl mice the expression 
of GHSR-1A was observed in the PPTg, but not in the LDTg (Zigman 
et al, 2006). Even though the involvement of PPTg cannot be 
excluded, it appears less likely since microinfusions of ghrelin into 
regions dorsal, ventral and lateral LDTg were preformed (i.e. in animals 
where the guid cannula was misplaced). In these cases no effect of 
ghrelin on either locomotor activity or extracellular concentration of 
accumbal DA was observed.  
 
The stimulatory and dopamine-enhancing 
effects of ghrelin are mediated via central 
nicotinic acetylcholine receptors (Paper II) 
Taken together, the results from Paper II and III suggest that ghrelin 
activates the cholinergic-dopaminergic reward link. The fact that 
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ethanol also has been shown to activate this reward link (e.g. Larsson et 
al, 2005; Paper I), indicates neurochemical analogies between ethanol 
and ghrelin. To this end, we have investigated the role of nAChRs, e.g. 
those in the VTA, for the stimulatory and DA enhancing effects of 
ghrelin. 
We have demonstrated (Paper II) that systemic pre-treatment with the 
unselective nicotinic antagonist, MEC, inhibits the stimulatory and DA 
enhancing effects of icv administration of ghrelin (Fig. 14), indicating 
that these effects of ghrelin are mediated via cholinergic mechanisms 
e.g. in the brain.  
 
 
Fig. 14. Systemic administration of the unselective nicotine antagonist MEC 
(2.0 mg/kg) antagonizes the ghrelin (1μg in 1μl)-induced accumbal dopamine 
overflow in mice measure by in v i v o microdialysis.  
MEC was administered at 0 minutes and ghrelin at 10 minutes. Shown are mean values 
S.E.M. of 4-5 observations in each group. The squares represent vehicle-ghrelin, the 
circles represent vehicle-vehicle, the triangles mecamylamine-vehicle and rhomb 
represent mecamylamine-ghrelin treatment. p<0.05, unpaired t-test, following a 
significant ANOVA. 
 
Further support for the involvement of cholinergic mechanisms is the 
results demonstrating that smoking or alcohol consumption in 
adolescent has been positively correlated to apparent eating patterns 
(e.g. Welsh and Fairburn, 1998; Wiseman et al, 1998; Anzengruber et al, 
1996). Given the neurochemical analogy between ethanol and ghrelin 
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and that ?CtxMII-sensitive receptors in the VTA appear to be 
involved in mediating the behavioural and neurochemical effects of 
ethanol (Larsson et al, 2004; Löf, 2006; Paper I), it may be implicated 
that these effects of ghrelin are mediated via similar nAChR subunits. 
This was further investigated in Paper IV.  
 
The stimulatory and dopamine-enhancing 
effects of ghrelin are mediated via the ?3?2*, 
?3* and/or ? 6* rather than the ? 4? 2* or ?7* 
subtypes (Paper IV) 
We showed (Paper IV) that infusion of the unselective nicotinic 
antagonist, MEC, into the VTA inhibits the stimulatory effects of 
ghrelin administered into the VTA or the LDTg. Further, neither 
systemic administration of DH?E (selective for the ?4?2* subunits) 
nor MLA (selective for the ?7* subunit), blocked the stimulatory 
effects of ghrelin infused into the VTA or the LDTg. Additionally, it 
was demonstrated that administration of ?CtxMII (selective for the 
?3?2*, ?3* and ?6* subunits), into the VTA antagonizes the stimulatory 
and DA enhancing effects of administration of ghrelin into either the 
LDTg (Fig. 15A) or the VTA (Fig. 15B). This suggests that the 
behavioural and neurochemical effects of ghrelin are mediated via 
?CtxMII-sensitive receptors, preferably the ?3?2*, ?3* and/or ?6*, 
rather than the ?4?2* and the ?7*, nAChRs in the VTA. This raises the 
possibility that ghrelin activates the cholinergic-dopaminergic reward 
link, via GHSR-1A in the LDTg as well as in the VTA. 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 70 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15. ?-conotoxin MII (50 pmol in 1 μl) antagonizes the stimulatory effects 
of ghrelin administered into the ventral or laterodorsal tegmental area 
A. Unilateral administration of ?-conotoxin MII (?CtxMII; 50 pmol in 1 μl) into the 
ventral tegmental area (VTA) antagonizes the stimulatory effects of ghrelin (2 μg in 1 
μl) administered into the laterodorsal tegmental area (LDTg), on the extracellular 
concentration of dopamine (DA) in nucleus accumbens (N.Acc.) in mice measured by 
in vivo microdialysis. B. Unilateral administration of ?CtxMII (50 pmol in 1 μl)  into 
the VTA antagonizes the stimulatory effects of ghrelin (2 μg in 1 μl) administered into 
the VTA, on the extracellular concentration of DA in N.Acc. in mice measured by in 
vivo microdialysis. 
?CtxMII was administered at -20 minutes and ghrelin at 0 minutes. Shown are mean 
values ± S.E.M. Two-way ANOVA showed statistically significant effects of 
treatment, ** p<0.01, *** p<0.001 Fisher post-hoc test. 
 
The lack of effects of DH?E or MLA on ghrelin-induced locomotor 
stimulation are in line with the previous results on ethanol showing 
that neither DH?E nor MLA antagonized the ethanol-induced 
locomotor stimulation and accumbal DA overflow (Larsson et al, 
2002) and that DH?E did not reduce ethanol consumption in rats in a 
limited access paradigm (Lê et al, 2000). However, it may be argued 
that the these drug do not pass the BBB or that the doses used were 
two low. The first possibility seems less likely since both DH?E 
(Bowman and Rand, 1980) and MLA (Turek et al, 1995) have been 
shown to penetrate the blood–brain barrier. Additionally, the ?4?2* 
 71 
(using DH?E) and ?7* (using MLA) subunits have been demonstrated 
to play a critical role in behavioural and neurochemical effects of 
nicotine (see e.g. Stolerman et al, 1997; Schilström et al, 1998b; Larsson 
et al, 2002; Ericsson et al, 2003); thus indicating that the doses used are 
relevant and that the drugs pass the BBB. Moreover, by increasing the 
doses of either MLA or DH?E the subunit selectivity may be lost (see 
e.g. Buisson et al, 1996).  
 
The stimulatory and DA enhancing effects of ethanol are mediated via 
?3?2* and/or ?3*, rather then the ?4?2*, ?7* and ?6*, subtypes (Larson 
et al, 2002; Larsson et al, 2004; Paper I). Moreover, the ventral 
tegmental ?3?2*, ?3* and/or ?6*, rather then the ?4?2* and ?7*, 
subtypes appear to have a central role for ghrelin-induced locomotor 
stimulation and accumbal DA overflow. Given that both ethanol and 
ghrelin activate the cholinergic-dopaminergic reward link, 
neurochemical analogies between ghrelin and ethanol may be 
implicated. It may therefore be hypothesized that the ?3?2* and/or 
?3*, rather than the ?6*, ?7* and ?4?2* nAChRs, may be a common 
denominator for the stimulatory and DA enhancing effects of ethanol 
as well as ghrelin. 
 
Nicotine, but not ghrelin, displace the [3H]-
nicotine binding in tissues from the ventral 
tegmental area (Paper IV) 
Given that ghrelin into the VTA increases the locomotor activity and 
accumbal DA overflow (Paper III, IV) and that these effects are 
mediated via ventral tegmental nAChRs (Paper IV) the possibility that 
ghrelin interacts directly with nAChRs in the VTA and thereby 
activates the mesolimbic DA system should be raised. In the present 
paper we showed that nicotine, but not ghrelin, displaces the [3H]-
nicotine binding in tissues form the VTA (Fig. 16), indicating that 
ghrelin does not interact directly with ventral tegmental nAChRs. 
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Fig. 16. Nicotine, but not ghrelin, displaces the binding of [3H]-nicotine in 
tissue from rat ventral tegmental area.  
Data poled from two experiments. 
 
In summary, the stimulatory and DA enhancing effects of ethanol as 
well as ghrelin appear to be mediated via ?CtxMII-sensitive nAChRs, 
e.g. ?3?2* and/or ?3* subtypes, in the VTA. This further supports the 
existence of a neurochemical analogies between ethanol and ghrelin, i.e. 
their ability to activate the cholinergic-dopaminergic reward link. 
 
Summary of results 
- A slightly modified method for synthesizing ?CtxMII peptide 
analogues was established. 
- ?CtxMII-sensitive, rather than ?-CtxPIA-analogue-sensitive 
nAChRs, i.e. the ?3?2* and/or ?3*, rather than the subunits 
?6*, in the VTA are involved in mediating the stimulatory and 
DA enhancing effects of ethanol in mice. 
- Administration of the orexigenic peptide ghrelin increased 
locomotor activity and the extracellular concentration of DA 
in the N.Acc. in mice. These results indicate that ghrelin 
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activates the mesolimbic DA system (i.e. the reward systems) 
and is a part of the neurochemical overlap between the reward 
systems and those regulating energy balance. 
- Administration of ghrelin into the VTA or LDTg (important 
brain reward nodes expressing GHSR-1A) increased the 
locomotor activity and accumbal DA overflow in mice, 
suggesting that ghrelin activates the cholinergic-dopaminergic 
reward link, probably via GHSR-1A in the VTA and LDTg. It 
is thus hypothesized that ghrelin may have incentive value for 
motivated behaviours such as meal initiation and/or food-
seeking. 
- Systemic administration of the unselective nicotinic antagonist, 
MEC, significantly inhibited the stimulatory and DA 
enhancing effects of ghrelin (icv), implying that cholinergic 
mechanism in the brain, i.e. nAChRs, are involved in 
mediating these behavioural and neurochemical effects and 
that ghrelin activates the cholinergic-dopaminergic reward 
link. 
- Infusion of the unselective nicotinic antagonist, MEC, into the 
VTA inhibited the stimulatory effects of ghrelin injected into 
the VTA or the LDTg. However, neither systemic 
administration of DH?E (selective for the ?4?2* subunits) nor 
MLA (selective for the ?7* subunit), blocked the stimulatory 
effects of ghrelin infused into VTA or the LDTg, indicating 
that ventral tegmental nAChR, but not the ?4?2* or the ?7* 
subunits, appear to be involved in mediating the stimulatory 
effects of ghrelin. 
- Administration of ?CtxMII (selective for the ?3?2*, ?3* and 
?6* subunits), into the VTA antagonized the stimulatory and 
accumbal DA enhancing effects of ghrelin injected into the 
VTA or the LDTg. Neurochemical analogies between ethanol 
and ghrelin can be implicated, suggesting that the behavioural 
and neurochemical effects of ghrelin, as well as ethanol, are 
mediated via ?CtxMII-sensitive receptors, preferably the 
?3?2* and/or ?3* subtypes, in the VTA.  
- In a radioligand-binding assay ghrelin does not displace the 
binding of [3H]-nicotine in tissue from the VTA, suggesting 
that ghrelin does not interact directly with ventral tegmental 
nAChRs. 
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General discussion 
Ethanol and the cholinergic-dopaminergic 
reward link 
The stimulatory and DA enhancing effects of ethanol were found to 
be mediated via ?CtxMII-sensitive, rather than ?CtxPIA-analogue-
sensitive, nAChRs in the VTA (Paper I). From the present 
experiments it cannot be determined whether these effects of ethanol 
are mediated by direct and/or indirect mechanisms in the VTA. 
Considering the first possibility, electrophysiological studies have 
suggested that ethanol acts as a co-agonist to ACh on nAChRs 
(Forman et al, 1989; Wu et al, 1994; Forman and Zhou, 1999; 
Marszalec et al, 1999). This effect is dependent on the ?-subunit (Zou 
et al, 2002), implying that ethanol may interact directly with nAChRs, 
possibly the ?3 subunit, on dopaminergic cell bodies in the VTA. 
However, this appears less likely since it has been found that acute 
ethanol application has no effect at least on human recombinant ?3?2* 
and ?3?4* nAChRs expressed in oocytes (Cardoso et al, 1999). 
Considering that rats demonstrate a concomitant increase in ventral 
tegmental ACh and accumbal DA overflow during voluntary ethanol 
consumption (Larsson et al, 2005), and that nAChR in the VTA 
mediate the stimulatory, rewarding and DA enhancing effects of 
ethanol (e.g. Blomqvist et al, 1997; Ericsson et al, 1998; Larsson et al, 
2002; Larsson et al, 2004; Paper I), it may be inferred that ethanol 
activates the cholinergic-dopaminergic reward link. More specifically, 
ethanol may, via activation of the mesopontine cholinergic input to the 
VTA, cause release of ACh in the VTA and thereby, via ?3?2* and/or 
?3* nAChRs, excite the mesolimbic DA system. Additionally, 
administration of MEC into the VTA blocks the increased accumbal 
DA caused by anticipation of ethanol (Löf, 2006), implying that 
alcohol seeking behaviour may also involve the cholinergic projections 
to the VTA.  
 
In all probability, ethanol may activate the mesolimbic DA system at 
several different levels, such as the N.Acc., the VTA and the LDTg. 
Reverse microdialysis of ethanol into the N.Acc. increases DA 
overflow in the N.Acc. (Ericson et al, 2003; Tuomianen et al, 2003, 
Löf et al, 2007b). However, ethanol-induced DA overflow in the 
N.Acc. is not directly related to the concentration of ethanol that 
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reaches the N.Acc. (Doyon et al, 2003; Löf et al 2007a). On the other 
hand, ethanol infusion into the anterior VTA does not affect accumbal 
DA levels (Ericson et al, 2003; Tuomianen et al, 2003; Löf et al, 
2007b). The VTA is nonetheless a heterogeneous brain structure, 
which integrates various afferents from several brain regions. The 
anterior versus the posterior part of the VTA differ in dopaminergic 
cell morphology, topography of their efferent projections, and 
presumably in function. In support of this hypothesis, it has been 
demonstrated that caudoventral DA neurons are more active during 
the rat’s active dark period, whereas rostrodorsal DA neurons are 
active during the light period (Luo and Aston-Jones, 2006). 
Additionally, we have found that perfusion of ethanol into the 
posterior VTA, but not into the anterior VTA, dose-dependently 
increased the extracellular levels of DA in N.Acc. (unpublished data). 
Similarly, rats voluntarily self-administer ethanol, cholinergic agonists 
or acetaldehyde into the posterior, but not anterior, part of the VTA 
(Gatto et al, 1994; Rodd-Henricks et al, 2000; Ikemoto and Wise, 2002; 
Rodd et al, 2004; Rodd et al, 2005). Co-administration of ethanol with 
the DA D2 receptor agonist quinpirole, which selectively inactivates 
dopaminergic neurons, into the posterior, but not anterior, VTA 
extinguished the maintenance of ethanol self-infusion (Rodd et al, 
2004). Furthermore, administration of quinpirole into the 
posteriomedial, but not the interolateral, VTA disrupted condition 
place preference induced by food rewards, whereas no effect on food 
intake per se was observed (Liu and Ikemoto, 2006). It may therefore be 
suggested that dopaminergic neurons in the posteriomedial, rather than 
anterior, part of the VTA are involved in the mediation of natural as 
well as drug-induced reinforcement. 
 
Ghrelin and the cholinergic-dopaminergic 
reward link 
The present thesis shows that ghrelin stimulates the cholinergic-
dopaminergic reward link via GHSR-1A in the VTA and/or LDTg. 
With regard to the possibility of ghrelin interactions in the LDTg, we 
suggest that ghrelin, via GHSR-1A in the LDTg, activates the 
cholinergic input to the VTA, causing a release of ACh which 
stimulates ventral tegmental nAChRs, preferentially of the ?3?2* 
and/or ?3* subtypes, thereby increasing mesoaccumbal DA levels and 
locomotor activity. However, this remains to be verified by e.g. 
measuring ACh release in the VTA after ghrelin administration into 
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the LDTg. In fact, the cholinergic LDTg projection to the VTA has 
been found to be involved in the regulation of the activity of the 
mesolimbic DA system as measured by locomotor stimulation and 
accumbal DA overflow. Thus, lesions of the LDTg blunt the 
stimulatory effects of nicotine (Alderson et al, 2005) as well as 
amphetamine-induced locomotor stimulation and increased accumbal 
DA overflow (Forster et al, 2002). Further support for this idea is 
provided by the finding that MEC antagonizes cocaine self-
administration (Levin et al, 2000) as well as cue-elicited cocaine craving 
in humans (Reid et al, 1999).  
 
In addition to GHSR-1A in the LDTg, we found that GHSR-1A in the 
VTA may be involved in the effects of ghrelin on the cholinergic-
dopaminergic reward link. Double-labelling studies in rats and mice 
have demonstrated both pre- and post-synaptic GHSR-1A in the VTA 
(Abizaid et al, 2006a). From the present series of experiments it cannot 
be determined whether pre- and/or post-synaptic GHSR-1As are 
involved. Ghrelin may act on pre-synaptic GHSR-1A situated on 
cholinergic or other excitatory e.g. the glutamatergic afferents. Thus, 
the competitive glutamate antagonist AP5 blocks the ghrelin-induced 
DA-firing in VTA slices (Abizaid et al, 2006b). However, the 
possibility that ghrelin interacts with post-synaptic GHSR-1A located 
on the DA cell bodies should also be taken into consideration (Abizaid 
et al, 2006a). With regards to this possibility, it should be emphasized 
that functional cholinergic projections to the VTA appear to be 
essential for the ability of drugs of abuse to activate the mesolimbic 
DA system (Reid et al, 1999; Levin et al, 2000; Forster et al, 2002; 
Alderson et al, 2005). 
 
Ghrelin stimulates a food-seeking behaviour 
Ghrelin increases food intake (Kamegai et al, 2001; Wren et al, 2001b; 
Theander-Carrillo et al, 2006) and stimulates food-seeking behaviour 
(Paper II; Paper III; Paper IV), effects possibly mediated via different 
neuronal systems. The ghrelin-induced feeding has been found to 
depend on GHSR-1A in the arcuate nucleus (Wren et al, 2001b; Rüter 
et al, 2003) and is likely to be mediated via NPY/AgRP projections 
(Kamegai et al, 2001; Chen et al, 2004). Additionally, GH-receptors 
(Egecioglu et al, 2006), orexin (Toshinai et al, 2003), POMC (Cowley 
et al, 2003) and MC containing (Chen et al, 2004) neurons seem to be 
involved. Nevertheless, a role of ghrelin in hunger, meal initiation (e.g. 
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Arvat et al, 2000; Tschöp et al, 2000; Horvath et al, 2001; Nakazato et 
al, 2001; Schmid et al, 2005) and foraging (Keen-Rhinehart and 
Bartness, 2004) has been suggested. We propose that ghrelin stimulates 
food-seeking behaviour via activation of the cholinergic-dopaminergic 
reward link. In fact, accumbal DA is involved in mediating the 
willingness of an animal to engage in motivated behaviours, e.g. 
foraging (for review see Berridge, 1996; Berridge and Robinson, 1998; 
Kringelbach, 2004; Kalivas and Volkow 2005). It is therefore 
conceivable that ghrelin has, at least in situations without food, 
incentive value for goal-directed behaviours such as food-seeking 
behaviour.  
Additionally, GHSR-1A in the VTA, via activation of the mesolimbic 
DA system, may regulate elemental feeding behaviour (Naleid et al, 
2005; Abizaid et al, 2006a). Furthermore, our preliminary data show 
that food presentation reduces ghrelin (icv)-induced locomotor 
stimulation and increases food intake (unpublished data). It may 
therefore be suggested that ghrelin induces foraging in animals without 
access to food, whereas animals presented with food choose to 
consume rather than seek food. Thus, centrally acting ghrelin appears 
to regulate energy homeostasis by increasing food intake via the 
arcuate nucleus, and by stimulating food-seeking behaviour via the 
cholinergic-dopaminergic reward link (Fig. 17).  
 
The DA reward systems are interconnected with a number of brain 
regions, which may be involved in the present effects. One possibility 
is that ghrelin induces foraging via projections between the 
cholinergic-dopaminergic reward link and the lateral hypothalamus. 
Orexin containing projections from the lateral hypothalamus to the 
VTA have been demonstrated to regulate the activity of ventral 
tegmental DA neurons (Fadel and Deutch, 2002) and they are essential 
for the acquisition of morphine-induced condition place preference 
(Wimmer et al, 2006). Additionally, orexin in the VTA is involved in 
the mediation of reinstatement of cocaine or morphine seeking as well 
as in the development of cocaine-mediated behavioural sensitization 
(Boutrel et al, 2005; Harris et al, 2005; Borgland et al, 2006). It is 
therefore plausible that ghrelin, via orexin projections to the VTA, 
activates the mesolimbic DA system and causes food-seeking 
behaviour, thus integrating functions of homeostatic and hedonic sites 
(Fig. 17). However, this needs to be further elucidated, e.g. by studying 
the effects of ghrelin into the arcuate nucleus on food-seeking 
behaviour. Furthermore, chronic food deprivation in rats induces 
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weight loss (Pothos et al, 1995) and increases drug-seeking behaviour 
(Carroll et al, 1979; Carroll and Stoltz, 1983). Food restriction 
enhances the plasma levels of ghrelin (Gualillo et al, 2002), implying 
that ghrelin may induce drug-seeking behaviour via activation of the 
cholinergic-dopaminergic reward link. Further support for a role of 
ghrelin in drug-seeking behaviour may be derived from the recent data 
showing a correlation between serum ghrelin levels and cocaine-
seeking behaviour (Tessari et al, 2007). 
 
Fig. 17.  Ghrelin may regulate food-seeking behaviour and food intake via 
different neuronal systems. 
ACh, acetylcholine; AgRP, agouti-related peptide; DA, dopamine; GABA; gamma-
aminobutyric acid; NPY, neuropeptide Y; POMC, proopiomelanocortin; LDTg, 
laterodorsal tegmental area; VTA, ventral tegmental area; N.Acc., nucleus accumbens, 
LH, lateral hypothalamus; Arc, arcuate nucleus; GHSR, growth hormone secretagogue 
receptor; nAChR, nicotinic ACh receptor. 
 
 79 
Ghrelin and compulsive overeating 
If feeding was controlled solely by homeostatic mechanisms, our ideal 
body weight would be easily maintained (for review see Saper et al, 
2002). However, many anorexigenic/orexigenic peptides, including 
ghrelin, are also integrated in the reward systems (Thiele et al, 2003; 
Thiele et al, 2004; Paper II Paper III; Paper IV), intrinsically 
reinforcing “non-homeostatic” food-consumption (for review see 
Saper et al, 2002) and thereby increasing the complexity of body 
weight regulation. Peripheral hyperghrelinemia is associated with binge 
eating in bulimic/anorectic subjects (Tanaka et al, 2003a) and 
hyperphagia in Prader-Willi patients (Cummings et al, 2002a; for 
review see Chanoine 2005). Additionally, high ghrelin protein levels, as 
well as mRNA expression in the hypothalamus, have been 
demonstrated in patients with obesity (Couce et al, 2006), implying that 
peripheral and/or central hyperghrelinemia might be involved in the 
pathophysiology of compulsive overeating in anorexia/bulimia 
/Prader-Willi and/or in obesity respectively. When taken into account 
that compulsive overeating has been associated with aberrations in the 
central DA system (e.g. Volkow et al, 2003a; Shapira et al, 2005) and 
that ghrelin activates the mesolimbic DA system (Naleid et al, 2005; 
Paper II; Abizaid et al, 2006a; Paper III; Paper IV), it might be 
suggested that a ghrelin dysbalance/dysfunction causes abnormalities 
in the mesolimbic DA system and thereby induces compulsive 
overeating (i.e. addictive behaviour). 
 
Nicotine, amphetamine and cocaine all induce satiety (Hollister, 1971; 
Grunberg et al, 1986; Mark et al, 1999), whereas ethanol (Hollister, 
1971; Yeomans et al, 1999) and ghrelin (e.g. Arvat et al, 2000) increase 
appetite and hunger. Satiety has been suggested to be associated with 
increased ACh (Rada et al, 2005), together with high DA (Rada et al, 
2001) levels in N.Acc.. These effects have been observed after food 
intake (e.g. Hernandez and Hoebel, 1988; Mark et al, 1992) as well as 
after nicotine, amphetamine or cocaine administration (Di Chiara and 
Imperato, 1988; Lindefors et al, 1992; Mark et al, 1999; Rada et al, 
2001). On the other hand, hypothalamic infusion of the orexigenic 
peptide galanin decreases accumbal ACh and increases accumbal DA 
(Rada et al, 1998). In contrast to this, ethanol has no effect on ACh in 
the N.Acc. in vivo (Rada et al, 2004b). Given the neurochemical 
analogies between ethanol and ghrelin, it may be speculated that 
ghrelin has no effect on accumbal ACh and thus does not induce 
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satiety. However, this needs to be further investigated. In addition, a 
role for 5-HT in satiety has been suggested (Gamaro et al, 2003). Thus, 
drugs that enhance 5-HT in the dorsal raphe reduce food intake, 
whereas drugs that inhibit the release of 5-HT stimulates food intake 
(Ohliger-Frerking et al, 2002). The ghrelin-induced feeding may thus 
partly be due to its ability to reduce the release of 5-HT in 
hypothalamic synaptosomes (Brunetti et al, 2002). It is also plausible 
that satiety, food intake and food-seeking behaviour are mediated via 
separate neuronal systems in the brain. 
 
Ghrelin and drugs of abuse 
An association between drugs of abuse and ghrelin has been shown. 
Smoking or methamphetamine administration acutely increases the 
plasma levels of ghrelin (Bouros et al, 2006; Fagerberg et al, 2003; 
Crowley et al, 2005). Further, systemic ghrelin enhances cocaine-
induced locomotor stimulation as well as condition place preference in 
rats (Wellman et al, 2005; Davis et al, 2007). High plasma ghrelin levels 
have been positively linked to craving during ethanol withdrawal 
(Addolorato et al, 2006), preferably in patients of Lesh’s type 1 
(Hillemacher et al, 2007). Individuals with high craving rates are more 
likely to relapse, implicating that high ghrelin levels during ethanol 
withdrawal may be involved in craving and thus cause relapse. An 
increased desire for sweet-tasting and high caloric food, have been 
shown to occur as a consequence of withdrawal in human alcoholics 
(for review see Kampov-Polevoy, 1999; Junghanns et al, 2000), 
especially in those with a family history of alcoholism (Jughanns et al, 
2005). High ghrelin levels in ethanol withdrawal (Kim et al, 2005) may 
cause food-seeking behaviour and thus increase the intake of high 
caloric food. The possibility that patients compensate for the lack of 
drug-induced reward by increasing their consumption of other rewards 
such as sucrose cannot be excluded (e.g. Junghanns et al, 2000). 
However, it should be considered that several substrates collectively 
enhance the desire to consume sweets during withdrawal. 
 
The plasma levels of ghrelin are elevated in alcohol dependent patients 
(Kim et al, 2005; Kraus et al, 2005), suggesting that ghrelin may be 
involved in the mediation of ethanol consumption and/or seeking. We 
recently conducted preliminary experiments showing that icv 
administration of ghrelin increases ethanol intake (Fig. 18) and 
preference and decreases water intake in a free choice limited access 
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paradigm in mice. The ghrelin system may thus constitute a novel 
potential target for future treatment of alcoholism.  
 
Fig. 18. The effects of ghrelin (2 μg) or an equal volume (1 μl) of vehicle 
solution administered into the third ventricle on ethanol intake in a limited 
access paradigm. 
Ghrelin significantly increases the ethanol intake compared to baseline (postop) as well 
as vehicle solution. p< 0.05, paired t-test. 
 
Given that ghrelin modulates ethanol intake it may be implied that this 
may be due to the high caloric properties of ethanol and that mice 
consume calories from ethanol instead of food. However, alcohol 
drinking acutely attenuates circulating ghrelin levels (Calissendorff et 
al, 2005; Zimmermann et al, 2007), an effect more pronounced than 
what would be expected from the calories ingested with alcohol 
(Calissendorff et al, 2006). Additionally, there is minimal evidence for 
any compensatory reduction in food intake in response to energy 
ingested as alcohol (for review see Yeomans, 2004). Alternatively, 
ghrelin could, via activation of the HPA-axis, augment the sensitivity 
of the mesolimbic DA system and thereby increase the ethanol intake. 
Intriguingly, ghrelin induces a prominent activation of the HPA axis 
(for review see Otto et al, 2005) such as elevating the plasma 
concentration of corticosterone (Jászberényi et al, 2006). It has 
previously been demonstrated that high plasma levels of corticosterone 
enhances DA release in the N.Acc. (Gianoulakis, 1998) and increases 
ethanol consumption (Fahlke et al, 1994; Hansen et al, 1994; Brady 
and Sonne, 1999).  
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Muscarinic acetylcholine receptors 
In addition to nAChR, ventral tegmental mAChRs appear to be 
involved in the ability of the LDTg to activate the DA neurons in the 
VTA (for review see Winn et al, 1997) and in natural reinforcement 
(Yeomans and Baptista, 1997; Rada et al, 2000; Sharf et al, 2006) and 
could possibly be involved in mediating the stimulatory and DA 
enhancing effects of ethanol as well as ghrelin. Our preliminary results 
show that the mAChR antagonist p-fluoro-hexaydro-silia-difendiol 
hydrochloride (selective for the M3/M5 subtypes), administered into 
the VTA reduces ethanol-induced locomotor stimulation. 
Furthermore, Western immunoblotting experiments demonstrate that 
the M5 subtype is expressed at approximately 20 % higher frequency 
in ethanol high-preferring than in low-preferring rats (unpublished 
data). The muscarinic antagonist, atropine, has further been found to 
decrease ethanol intake in rats (e.g. Wahlström and Nordberg, 1992). 
On the other hand, systemic injection of the unselective muscarinic 
antagonist, scopolamine, does not block the ghrelin-induced (icv) 
locomotor stimulation (unpublished data). Thus, mAChRs may also be 
involved in mediating the stimulatory effects of ethanol, but not of 
ghrelin, indicating that there are some differences in mode of action of 
the two substances. Furthermore, it should be emphasized that several 
other neurotransmitters besides DA, such as GABA, 5-HT, glutamate 
and opioid peptides, collectively orchestrate the rewarding properties 
of ethanol (see e.g. Engel et al, 1992), and possibly of ghrelin. Needless 
to say, other areas in the brain may also be involved in mediating the 
reinforcing properties of addictive drugs and natural rewards. A role 
for the lateral hypothalamus in brain reward has previously been 
suggested as rats self-administer electro-stimulation (Olds, 1958) or 
morphine  (Olds, 1979) into this area. Similarly, it has been 
demonstrated that hypothalamic electro-stimulation (Hernandez and 
Hoebel, 1988; Phillips et al, 1989) increases accumbal DA. 
Additionally, areas such as amygdala, hippocampus, orbifrontal cortex 
and dorsal striatum may have an important role in brain reward and 
drug-seeking behaviour (Volkow and Fowler, 2000; Volkow et al, 
2006; Zhao et al, 2006). 
 
Neurochemical analogies 
The ?3?2* and/or ?3*, rather than the ?6*, ?7* and ?4?2* nAChRs, 
may be a common denominator for the stimulatory and DA enhancing 
 83 
effects of ethanol as well as ghrelin (see Results and discussion), implying 
neurochemical analogies. It should be considered that the ?CtxMII-
sensitive nAChRs, e.g. ?3?2* and/or ?3* subtypes, might serve as novel 
pharmacological targets for development of treatment strategies for 
addictive behaviours, such as binge eating and alcoholism. 
Interestingly, it has been shown that MEC reduces the positive, e.g. 
stimulant and euphoric effects of ethanol drinking in healthy 
volunteers (Blomqvist et al, 2002; Chi and de Wit, 2003), but given that 
MEC is an unselective nicotinic antagonist it is not surprising to note 
that the number of side effects is large. On the other hand a selective 
antagonist at the ?3?2* and/or ?3* nAChRs, may be more efficient and 
may produce less side effects. However, ?CtxMII is a 16 amino acid 
peptide and is unlikely to pass the BBB thereby excluding it as a useful 
pharmaceutical agent. However, by elucidating the structure-activity 
relationship for ?CtxMII, e.g. by an alanine walk, a smaller compound 
with similar subunit selectivity could be developed.   
 
In summary, the present thesis suggests that both ethanol and ghrelin 
activate the cholinergic-dopaminergic reward link, implying 
neurochemical analogies. Specifically, we hypothesize that ethanol via 
the PPTg/LDTg and/or VTA stimulates the cholinergic projections to 
the VTA. We also suggest that ghrelin activates the cholinergic LDTg-
VTA projection via GHSR-1A in the LDTg as well as in the VTA. 
This causes a release of ACh which activates ventral tegmental 
nAChRs, preferably the ?3?2* and/or ?3* subtypes, and thereby 
increases mesoaccumbal DA levels and locomotor activity. The DA 
enhancing properties of ethanol may represent the rewarding feelings 
of ethanol. Moreover, the ghrelin-induced accumbal DA overflow 
causes locomotor stimulation, which may reflect a rewarding food-
seeking behaviour  (Fig. 19).  
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Fig. 19. Ethanol as well as ghrelin activate the cholinergic LDTg-VTA 
projection and thereby cause an increase in ventral tegmental ACh. This 
activates the mesolimbic DA system via ?CtxMII-sensitive receptors (e .g .  
?3?2* and/or ?3* subtypes) resulting in an accumbal DA release, which causes 
a locomotor stimulation, reward and/or food-seeking and drug-seeking 
behaviour. 
Ach, acetylcholine; DA, dopamine; LDTg, laterodorsal tegmental area; VTA, ventral 
tegmental area; N.Acc., nucleus accumbens; GHSR, growth hormone secretagogue 
receptor; nAChR, nicotinic ACh receptor. 
 
Concluding remarks 
Patients with alcoholism or aberrant eating patterns can be divided into 
defined subtypes, characterized by specific phenotypes such as the 
restrictive and binge eating types. Furthermore, bingeing individuals 
have higher scores for nicotine dependence and are more likely to 
smoke than their non-bingeing counterparts. Different 
pathophysiological mechanisms may in all probability underlie the 
characteristics of these various subtypes, e.g. ghrelin correlates with 
craving in Lesch’s type 1, but not type 2. Conceivably, the treatment 
strategies should be adjusted depending on the neurobiological basis of 
the patient’s subtype.  
 
Results presented in this thesis suggest that ghrelin and ethanol 
activates the cholinergic-dopaminergic reward link. Moreover, 
?CtxMII-sensitive (?3?2* and/or ?3*) nAChRs may mediate the 
behavioural and neurochemical effects of ethanol as well as of ghrelin. 
We hypothesize that these mechanisms also are involved in alcoholism 
and compulsive overeating. It is therefore intriguing to speculate that 
?3?2* and/or ?3* containing nAChRs may serve as potential novel 
pharmacological targets for treatment of some subtypes of alcoholism 
and deviant eating behaviours.  
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Swedish summary 
På 1950-talet upptäckte Olds och Milner att råttor självadministrerade 
elektrostimulering till vissa områden i hjärnan men inte till andra. Dessa 
djur slutade fokusera på naturliga belöningar såsom mat, och sex; de 
hade blivit elberoende. Områden involverade i detta fenomen 
identifierades och kom att kallas för hjärnans belöningssystem. 
Forskning har därefter visat att dessa system förmedlar de belönande 
egenskaperna hos naturliga belöningar, såsom mat, samt hos 
beroendeframkallande droger, t.ex. alkohol. Det har också 
demonstrerats att dessa system är viktiga för att förstärka och öka 
motivationen för inlärning av beteenden som i förlängningen ökar 
individens överlevnad, såsom att söka efter mat. En viktig del av 
hjärnans belöningssystem är det mesolimbiska dopaminsystemet. Detta 
består av dopaminneuron löpande från ventrala tegmentala arean 
(VTA) till nucleus accumbens (N.Acc.). Vidare verkar även de 
kolinerga projektionerna till VTA vara viktiga för de belönande 
egenskaperna hos droger och hos naturliga belöningar. Den idag kända 
kolinerga projektionen till VTA utgår framförallt från laterala dorsala 
tegmentala arean (LDTg) och den har föreslagits vara en viktig 
komponent i hjärnans belöningssystem. Tillsammans kallar vi detta för 
den kolinerga-dopaminerga belöningslänken (Fig. 20). Vid en 
obalans/dysfunktion i belöningssystemen kan ”addictive behaviours”, 
så som drogberoende, ätstörningar, sex- och spelmissbruk, utvecklas.  
 
 
Fig. 20. Den kolinerga-dopaminerga belöningslänken. 
Den kolinerga-dopaminerga belöningslänken består av en kolinerg projektion från 
laterodorsal tegmentala arean (LDTg) till ventrala tegmentala arean (VTA) och därefter 
det mesolimbiska dopaminsystemet, d.v.s. dopaminprojektionen från VTA till nucleus 
accumbens (N.Acc.). Aktivering av LDTg orsakar en frisättning av acetylkolin i VTA, 
vilket via påverkan av nikotinreceptorer och/eller muskarinreceptorer stimulerar det 
mesolimbiska dopaminsystemet och orsakar en frisättning av dopamin i N.Acc..  
 
Alkoholism är idag ett stort samhällsproblem och de alkoholrelaterade 
kostnaderna i Sverige uppskattas till tiotals miljarder kronor per år. Ett 
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äldre (Antabus?) och två nyare läkemedel (Campral? och Revia?) är 
idag godkända för behandling av alkoholberoende. Det har i kliniska 
studier visats att dessa dock inte fungerar optimalt och ett stort behov 
för ytterligare behandlingsstrategier finns. Genom att öka förståelsen 
av de mekanismer som är involverade i alkoholberoende kan nyare och 
bättre läkemedel utvecklas, vilket var ett av målen med denna 
avhandling.  
Tidigare forskning har visat att alkoholens stimulerande och belönande 
egenskaper är förmedlade via det mesolimbiska dopaminsystemet, 
vilket delvis representeras av en dopaminökning i N.Acc.. 
Verkningsmekanismen för alkohol är relativt okänd, men det har visats 
att alkohol interagerar med ligandstyrda jonkanaler i hjärnan, 
exempelvis nikotinreceptorn. Intressant nog, har det visat sig att det 
finns ett samband mellan alkohol- och nikotinintag bland alkoholister 
samt i normalpopulationen. Man har bland annat funnit att 80-90% av 
alla alkoholister också är storrökare och att alkoholism är cirka 10 
gånger mera vanligt hos rökare än icke-rökare. Dessutom har studier 
på friska frivilliga visat att alkohol förstärker nikotinets belönande 
egenskaper samt att en oselektiv nikotinreceptorblockerare 
(mekamylamin) minskar de positivt förstärkande effekterna av alkohol. 
Vår forskargrupp har tidigare visat att kronisk tillförsel av alkohol 
förändrade nikotininbindningen i hjärnan samt att nikotinreceptorer, 
framför allt de som finns i VTA, är involverade i att förmedla 
alkoholens stimulerande, dopaminökande och belönande egenskaper. 
Nikotinreceptorn består av fem stycken subenheter, som sitter ihop i 
en ringformation. Det finns många subenheter såsom ?, ? och ?, vilka i 
sin tur finns i olika former (t.ex. ?3-?10 och ?2-?4). De olika 
subenheterna kan kombineras på många olika sätt och därmed bilda så 
kallade subtyper av nikotinreceptorn. Eftersom de olika subtyperna av 
nikotinreceptorn har olika funktion, postulerar vi att vissa, men inte 
andra, subtyper är involverade i alkoholens belöningsprofil. Vi har 
därför tidigare genomfört en serie försök där vi med hjälp av olika 
nikotinreceptorblockerare, med selektivitet för olika subtyper, utrett 
vilken sammansättning av nikotinreceptorn som är av störst betydelse 
för alkoholens stimulerande, belönande och dopaminökande 
egenskaper. I tidiga försök har vi funnit att nikotinreceptorns ?3?2*, 
?3* och/eller ?6* (genom att använda ?-conotoxin MII), men inte 
?4?2* (genom att använda dihydro-?-erythroidine) eller ?7* (genom att 
använda methyllycaconitine) subenheter är involverade i alkoholens 
ovan nämnda effekter. 
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I delarbete I ville vi undersöka vilka av de ovannämnda subenheterna 
(?3?2*, ?3* och/eller ?6*) som är involverade i alkoholens stimulerande 
och dopaminökande egenskaper. I ett samarbete med 
läkemedelskemisterna professor Kristina Luthman och Morten Grøtli 
på Naturvetenskapliga fakulteten på Göteborgs universitet har vi 
utvecklat en metod för att göra nikotinreceptorblockerare med olika 
subenhetselektivitet. Först tillverkade vi nikotinreceptorblockeraren ?-
conotoxin MII, och fann att administration av vårt ?-conotoxin MII 
till VTA blockerade alkoholens stimulerande effekter, vilket stämmer 
överens med våra tidigare data med kommersiellt ?-conotoxin MII. 
Detta pekar att på att ?-conotoxin MII-känsliga nikotinreceptorer, 
förslagsvis ?3?2*, ?3* och/eller ?6* subenheterna, i VTA är 
involverade i att förmedla alkoholens stimulerande egenskaper samt att 
vår syntesmetod fungerade tillfredställande. Vi syntetiserade också en 
annan nikotinreceptorantagonist med selektivitet för nikotinreceptorns 
?6* subenhet, en ?-conotoxin PIA-analog. Vi fann att administration 
av vår ?-conotoxin PIA-analog till VTA inte blockerade alkoholens 
stimulerande och dopaminökande egenskaper. Sammantaget tyder 
detta på att nikotinreceptorns ?3?2* och ?3*, men inte ?6*, subenheter i 
VTA är involverad i alkoholens stimulerande och dopaminökande 
egenskaper. Tidigare försök från vår forskargrupp har visat att råttor 
som dricker alkohol får en frisättning av acetylkolin i VTA samtidigt 
med dopamin i N.Acc.. Vår övergripande arbetshypotes är därför att 
alkohol, via aktivering av den kolinerga-dopaminerga belöningslänken, 
orsakar en frisättning av acetylkolin i VTA vilket via interaktion med 
?3?2* och/eller ?3* subenheterna i VTA stimulerar det mesolimbiska 
dopaminsystemet. 
Denna belöningslänk anses också vara av central betydelse för de 
belönande egenskaperna hos naturliga belöningar, såsom mat. Det är 
idag allmänt accepterat att det finns ett neurokemiskt överlapp mellan 
belöningssystemen och de system som reglerar energibalansen, d.v.s. 
endogena substanser som både påverkar belöningssystemen och 
energibalansen. Ghrelin är en aptitökande peptid som till största delen 
bildas till i magsäcken, men mindre mängder produceras också i 
hjärnan. Eftersom ghrelin reglerar energibalansen ville vi i delarbete II, 
III och IV, undersöka om och hur ghrelin kan aktivera hjärnans 
belöningssystem. 
I samarbete med professor Suzanne Dicksons forskargrupp, har vi 
funnit att infusion av ghrelin till tredje ventrikeln hos möss (vilket gör 
att ghrelin kan ta sig in i hjärnan) ökar aktiviteten samt orsakar en 
frisättning av dopamin i N.Acc.. Detta har ghrelin gemensamt med 
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alkohol vilket tyder på att ghrelin är en spelare på belöningsplanen. 
Med utgångspunkt i att ghrelinreceptorer uttrycks i LDTg och VTA 
(områden förknippade med belöning och motivationshöjande 
beteende) ville vi undersöka om ghrelin stimulerar belöningssystemen 
via en aktivering av ghrelinreceptorer i dessa områden. Vi fann då att 
lokal injektion av ghrelin i LDTg eller VTA orsakar en motorisk 
stimulation samt en dopaminökning i N.Acc.. Detta tyder på att ghrelin 
stimulerar den kolinerga-dopaminerga belöningslänken. Denne effekt 
har ghrelin gemensamt med alkohol, vilket talar för neurokemiska 
likheter mellan ghrelin och alkohol. 
Eftersom nikotinreceptorer är involverade i alkoholens belöningsprofil 
föreslår vi att nikotinreceptor också medierar ghrelins stimulerande och 
dopaminökande egenskaper. Vi fann i en serie försök att en oselektiva 
nikotinblockerare (mekamylamin) blockerar ghrelinets ovannämnda 
egenskaper. Med bakgrund i våra tidigare försök med alkohol, som 
visar att alkoholen belöningsprofil är förmedlade via ?CtxMII-känsliga 
nikotinreceptorer, hypotiserade vi att ghrelins stimulerande och 
dopaminökande egenskaper också är förmedlade via ?CtxMII-känsliga 
nikotinreceptorer i VTA. I en serie försök fann vi att varken 
nikotinreceptorns ?4?2* (genom att använda dihydro-?-erythroidine) 
eller ?7* (genom att använda methyllycaconitine) subenheter är 
involverade i ghrelins stimulerande egenskaper. Vidare fann vi att 
injektion av ?CtxMII till VTA blockerar ghrelinets stimulerande och 
dopaminökande egenskaperna. Våra resultat vittnar om att ghrelin 
stimulerar den kolinerga-dopaminerga belöningslänken. Vi föreslår 
därför att ghrelin via aktivering av ghrelinreceptorer i LDTg och VTA, 
orsakar en frisättning av acetylkolin i VTA som i sin tur interagerar 
med ?CtxMII-känsliga nikotinreceptorer, förslagsvis ?3?2*, ?3* 
och/eller ?6* subenheter, och därmed stimulerar det mesolimbiska 
dopaminsystemet. Möjligheten att ghrelin interagerar direkt med 
nikotinreceptorer uteslöts eftersom ghrelin inte påverkar inbindningen 
av nikotin till nikotinreceptorer.  
Eftersom belöningssystemen framför allt är involverade motivations 
höjande beteenden så som aktivt sökande efter mat föreslår vi att 
ghrelin har ett förstärkande värde för motivations höjande beteenden. 
Vikten av detta är förslagsvis att ghrelin orsakar ett aktivt sökande efter 
mat (lokomotorstimulation) samt att sökandet i sig själv är belönande 
(dopaminökning i N.Acc.), vilket ökar sannolikheten för individens 
överlevnad (Fig. 21).  
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Fig. 21. Ghrelin framkallar ett belönande sökande efter mat via aktivering av den 
kolinerga-dopaminerga belöningslänken. 
Ghrelin aktiverar, via ghrelinreceptorer i laterodorsala tegmentala arean (LDTg) och 
ventrala tegmentala arean (VTA), belöningssystemen, mer specifikt den kolinerga-
dopaminerga belöningslänken. Detta orsakar i sin tur en frisättning av acetylkolin i 
VTA vilket via interaktion med ?CtxMII-känsliga nikotinreceptorer, förslagsvis ?3?2* 
och/eller ?3* subenheter, stimulerar det mesolimbiska dopaminsystemet. Denna 
stimulering leder till ett födosökande beteende (lokomotorstimulation) som i sig är 
belönande.  
 
Sammanfattningsvis pekar detta på att ghrelin liksom alkohol aktiverar 
den kolinerga-dopaminerga belöningslänken samt att ?CtxMII-känsliga 
nikotinreceptorer i VTA har en central betydelse för ghrelins och 
alkohols effekter. Detta tyder på neurokemiska likheter mellan ghrelin 
och alkohol. 
Eftersom förändrade ghrelinnivåer i blodet är kopplade till hetsätningar 
(som är inkluderade i ”addictive behaviours”) samt att hetsätningar är 
associerade till belöningssystemen, föreslår vi att ghrelins aktivering av 
belöningssystemen kan vara en del av hetsätningens patofysiologi. 
Sammantaget öppnar detta möjligheten för att ?CtxMII-känsliga 
nikotinreceptorer, förslagsvis ?3?2* och/eller ?3* subenheterna, skulle 
kunna vara ett potentiellt mål för utveckling av nya behandlings-
strategier för ”addictive behaviours”, såsom hetsätningar och 
alkoholism. 
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